CURRICULUM VITAE **Andrew J. Vickers, Ph.D.**

Updated on: July 15, 2015

A. GENERAL INFORMATION

Name: Andrew J. Vickers

Office address: Memorial Sloan Kettering Cancer Center
485 Lexington Ave, 2nd FL, New York, NY 10017
Tel. #: 646 888 8233
Fax. #: 929 321 1516
Cell phone: 347 244 6934
Email: vickersa@mskcc.org
Website: http://www.mskcc.org/mskcc/html/3197.cfm

Citizenship: USA

B. EDUCATIONAL BACKGROUND

Degree	Institution	Dates Attended	Year awarded
BA	University of Cambridge, UK	10/86 – 06/89	1989
D.Phil. (doctorate)	University of Oxford, UK	09/96 – 10/99	1999

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

Post-doctoral training (include residency/fellowships)

Not applicable

Academic positions (teaching and research)

Title	Institution name and location	Dates held
Assistant Member	Memorial Sloan Kettering Cancer Center Department of Epidemiology and Biostatistics, Department of Medicine New York, NY	12/99-11/06
Assistant Professor of Public Health	Weill Cornell Medical College Department of Public Health New York, NY	01/04-10/07
Associate Member, Memorial Hospital	Memorial Sloan Kettering Cancer Center Department of Epidemiology and Biostatistics,	11/06-05/12

	Department of Medicine New York, NY	
Associate Professor of Public Health	Weill Cornell Medical College Department of Public Health New York, NY	11/07-06/13
Professor of Public Health	Weill Cornell Medical College Department of Public Health New York, NY	07/13-present
Member	Memorial Sloan Kettering Cancer Center Department of Epidemiology and Biostatistics, Department of Medicine New York, NY	05/12-present

Hospital positions (e.g., attending physician)

Title	Institution name and location	Dates held
Assistant Attending Research Methodologist	Memorial Hospital for Cancer and Allied Diseases Department of Epidemiology and Biostatistics, Department of Medicine New York, NY	12/99-11/06
Associate Attending Research Methodologist	Memorial Hospital for Cancer and Allied Diseases Department of Epidemiology and Biostatistics, Department of Medicine New York, NY	11/06-05/12
Attending Research Methodologist	Memorial Hospital for Cancer and Allied Disease Department of Epidemiology and Biostatistics, Department of Medicine New York, NY	05/12-present

Other Employment

Title	Institution name and location	Dates held
Care attendant	Crossroads Disability Scheme, London, UK.	10/90-01/91
Database assistant	Good Practices in Mental Health, London, UK.	02/91-01/93
Researcher, then Director of Research	Research Council for Complementary Medicine London, UK	02/93-07/99

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

Not applicable

E. PROFESSIONAL MEMBERSHIPS (medical and scientific societies)

Chair	Acupuncture Trialists' Collaboration	2007-present
Member	TRIPOD group	2010 - present

F. HONORS AND AWARDS

Raenaker's Prize for academic achievement. University of Cambridge	1989
CaPCure award for prostate cancer research. Prostate Cancer Foundation	2007

G. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Affiliation: Memorial Sloan Kettering Cancer Center

Other Affiliations: Weill Medical College of Cornell University

H. EMPLOYMENT STATUS

Memorial Sloan-Kettering Cancer Center: full-time salaried at Cornell-affiliated hospital.

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT

Teaching/Mentoring

Lecturer, preceptor: Statistics course for WMC medical undergraduates, 2000- 2012
Course leader: MSKCC biostatistics course, 2001-Present
Faculty: K30 grant in Clinical Research Methodology, 2001-Present
Mentor one member of junior faculty plus 2 – 4 research fellows per year

Clinical care (duties, dates)

Not applicable

Administrative duties, including committees, dates

Pain and Psychosocial Task Force, 2002-2003
Psycho-Oncology Work-in-Progress Research Colloquia, 2004-2006
Molecular Pathology Clinical Testing Advisory Group 2007 - 2013

Research

Biostatistician and research methodologist for numerous clinical trials and cohort studies in the Departments of Medicine, Surgery and Pediatrics as well as original methodological research for the Department of Epidemiology and Biostatistics, 1999 – present. PI on one completed and one ongoing IRB protocol.
Director, Web Survey Core Facility, 2013- Present

	Current Effort	WMC students or researchers?	MSKCC students or researchers?
Teaching / Mentoring	25%	Yes	Yes
Clinical Care	N/A	N/A	N/A
Administration	10%	No	Yes
Research	65%	No	Yes

J. RESEARCH SUPPORT

CURRENT

R01AT006794 (Vickers) 08/01/11 - 05/31/16
NCCAM $166,371 direct per year
Acupuncture Trialists' Collaboration: meta-analyses of chronic pain trials
Role: PI. Effort: 18.75%

R01CA179115 (Vickers) 08/01/14 - 07/31/19
NCI $374,625 direct per year
Dynamic, multi-cohort prediction modeling of prostate biopsy outcome
Role: Co-PI. Effort: 18.75%.

R01CA160816 (Vickers / Lilja) 08/08/12 - 05/31/16
NCI $352,560 direct per year
Prospective validation of a multi-marker prostate cancer prediction model
Role: Co-PI. Effort: 11.25%.

P50 CA092629 (Scher) 09/01/11 - 08/31/16
NIH $155,864 direct per year
Biostatistics core: SPORE in Prostate Cancer
Role: Biostatistician. Effort: 13.2%

P30 CA008748 (Thompson) 01/01/14- 12/31/18
NCI $70,480 direct per year
Cancer Center Support Grant: Web Core
Role: Co-Investigator. Effort: 15%

NIH-5-K30 (Imperato-McGinley) 07/01/12 - 06/30/17
NIH $229,923 direct per year
MSKCC Clinical Research Methodology Curriculum
Role: Leader of Biostatistics Course. Effort: 15%

R01 CA175491 (Klein) 01/04/13 - 04/31/18
NCI $280,636 direct per year
SNPs to interpret marker levels in prostate cancer
Role: PI. Effort: 5.6%.

COMPLETED

U01 CA157224 (Etzioni) 09/01/10- 07/31/15
NCI Consortium funding
Modeling Prostate Cancer Control: Prevention, screening, treatment, follow-up care
Role: Co-Investigator. Effort: 5%

NIH-5-K30-NL04160 (Bajorin) 07/01/99 - 06/30/04
NIH $ 176,650 direct per year
MSKCC Clinical Research Methodology Curriculum
Role: Course Leader of Biostatistics Course. Effort: 20%

Concept award (Cassileth) 03/01/01 - 02/29/04
Department of Defense $100,000 direct per year
D-Fraction Maitake for Breast Cancer: Preliminary research to determine viability for eventual Phase III Trials
Role: Biostatistician. Effort: 10%

R21 AT 01030-01 (O'Reilly) 10/01/01 - 09/30/03
NIH: NCI/ NCCAM $75,000 direct per year
Acupuncture treatment of chronic pain in pancreatic cancer
Role: Biostatistician. Effort: 5%

R21 AT 01030-01 (Cassileth) 10/01/01 - 09/30/03
NIH: NCI/ NCCAM $75,000 direct per year
Massage for treatment of pain in advanced cancer
Role: Biostatistician. Effort: 5%

R21 AT 01030-01 (Feinstein) 10/01/01 - 09/30/03
NIH: NCI/ NCCAM $50,000 direct per year
Acupuncture for shortness of breath in cancer patients
Role: Biostatistician. Effort: 5%

R21 CA96321-01 (Cheung) 07/01/02 - 06/30/04
NIH $125,000 direct per year
Phase I study of oral β-glucan and intravenous anti-GD2 monoclonal antibody 3F8 among patients with metastatic neuroblastoma
Role: Biostatistician. Effort: 10%

Concept award (Schwartz) 07/01/02 - 06/30/05
Department of Defense $100,000 direct per year
Phase I and II trials of a huanglian, a botanical, with or without Taxol, in breast cancer
Role: Biostatistician. Effort: 5%

R21 CA098565 (Cassileth) 01/01/03 - 12/31/04
NIH $150,000 direct per year
Pilot randomized trial of acupuncture for hot flashes in cancer patients
Role: Biostatistician. Effort: 5%

R21 CA98792-01 (Pfister) 01/01/03 - 12/31/04
NIH $125,000 direct per year
Pilot randomized trial of acupuncture for shoulder pain after neck dissection
Role: Biostatistician. Effort: 5%

R21 CA103169 (Vickers) 07/01/03 - 06/30/05
NIH $50,000 direct per year
Methodology of Phase I and II trials of anticancer CAM
Role: Principal Investigator. Effort: 25%

P50 AT002779 (Cassileth) 04/05/05 - 03/31/10
NIH $1,050,000 direct per year
MSKCC Research Center for Botanical Immunomodulators
Role: Biostatistician. Effort: 10%

R21 CA117076 (Kramer) 8/01/05-7/31/07
NIH $75,000 direct per year
Treating CNS Malignancies with 131-I-8H9
Role: Biostatistician. Effort: 5%

Prostate SPORE (Scardino) 09/01/05 - 08/31/06
NIH $1,814,066 direct per year
Role: Biostatistician. Effort: 20%

R01 FD003089-01131-1 (Kramer) 2/15/06 - 2/14/09
FDA $430,247 direct for 3 years

Phase I trial of 3F8 in Leptomeningeal Cancers
Role: Biostatistician. Effort: 5%

P01 (Petrek, MSKCC PI: Cordon-Cardo) 4/1/06 – 3/31/11
NCI $1,893,462 direct per year
Role and Regulation of p53
Role: Biostatistician. Effort: 10%

R33 CA118845 (Cheung) 4/1/06 - 3/31/11
National Cancer Institute $75,000 direct per year
A novel set of molecular markers to measure metastatic neuroblastoma
Role: Biostatistician. Effort: 5%

Experimental Therapeutics Committee (Kushner) 8/01/06-7/31/07
MSKCC $100,000 direct per year
Tetravalent vaccine for neuroblastoma
Role: Biostatistician. Effort: 5%

R21 (Cassileth) 01/01/07 - 12/31/08
NCI $100,000 direct per year
Randomized Phase II trial of acupuncture for post-thoracotomy pain
Role: Biostatistician. Effort: 5%

R21 (Deng) 01/01/07 - 12/31/09
NCI $100,000 direct per year
Randomized Phase II trial of acupuncture for post-operative ileus
Role: Biostatistician. Effort: 5%

R21 (Vickers) 03/01/08 - 02/28/11
NCCAM $100,000 direct per year
Acupuncture Trialists' Collaboration: meta-analyses of chronic pain trials
Role: PI. Effort: 15%

R21 (Vickers) 07/01/08 - 06/30/10
NCI $100,000 direct per year
Clinically integrated trial of modifications to radical prostatectomy
Role: PI. Effort: 15%

T32 CA082088 (Scardino) 03/01/09 - 02/28/10
NIH $233,544 direct per year
Urologic Oncology Research Training Grant
Role: Preceptor. Effort: No salary support

U24 (Tempst) 01/01/07 - 12/31/12
NCI $200,000 direct per year
Proteomics development grant
Role: Biostatistician. Effort: 5%

NIH-5-K30-NL04160 (Bajorin) 07/01/07 - 06/30/12
NIH $256,000 direct per year
MSKCC Clinical Research Methodology Curriculum
Role: Leader of Biostatistics Course. Effort: 10%

NIH-5-K30-NL04152 (Imperato-McGinley) 07/01/07 - 06/30/12
NIH Consortium funding
Cornell Clinical Research Methodology Curriculum
Role: Leader of Biostatistics Course. Effort: 10%

R33 CA127768-02 (Lilja) 08/01/10- 07/31/12
NIH $200,000 direct per year
Long-term prediction of prostate cancer
Role: Biostatistician. Effort: 15%

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Positions

1995-2015	Editorial Board of *Complementary Therapies in Medicine*
1995-9	Randomized trials search co-ordinator for Complementary Medicine field of the Cochrane Collaboration
1997-9	Editor of *Complementary Therapies in Medicine*.
2001+	Editorial Board for *Biomed Central Cancer*, *Biomed Central Medical Research Methodology*, *Biomed Central Complementary and Alternative Medicine*
2001- 3	Expert panel on complementary and alternative medicine research methodology: symptom control. National Cancer Institute.
2002 - 4	NIH study section: NCCAM Special Emphasis Panel: Cancer
2002+	Associate Editor of *CA: a Cancer Journal for Clinicians*
2004	Editorial Advisory Board: Complementary and Alternative Medicine PDQ (National Cancer Institute)
2004	NIH study section: NCI Special Emphasis Panel: cancer training programs
2004	NIH study section: NCI Special Emphasis Panel: Phase I trials of botanicals and supplements
2007	NIH study section: NCI Special Emphasis Panel: cancer education
2007 +	Associate Editor for *Trials*
2010	New York Governor's Panel on Prostate Cancer Awareness
2010-2	NIH study section: Biostatistical Methods and Research Design
2010-2	DSMB Kang Laite studies
2011+	NCCN guidelines: Prostate cancer early detection
2012+	ASCO guidelines on PSA screening

2012-13	DSMB chair: Statin discontinuation trial
2013+	Statistical editor for *European Urology*
2013+	Editorial board: *Medical Decision Making*
2104+	Advisory board: PHOTO trials

Key Invited External Lectures

March 1994	Quality in Complementary Medicine. British Medical Association.
April 1994	Acupuncture. Food and Drug Administration, USA.
June 1994	Documentation as a Basis for Research in Integrated Medicine. Wiener Internationale Akademie für Ganzheitsmedizin, Austria.
July 1994	Examining Research Assumptions in Alternative Medical Systems. Office of Alternative Medicine of the National Institutes of Health, USA.
July 1994	National Staff Nurses Conference. Bath, UK.
October 1994	Complementary Medicine in the NHS. British Holistic Medical Association / Guy's Hospital/ University of Westminster.
April 1995	Research Methodology in Alternative and Complementary Medicine. Office of Alternative Medicine, National Institutes for Health, USA.
May 1995	Evidence Based Purchasing. Oxford and Anglia RHA.
February 1996	Commissioning Complementary Medicine. East London & City Health Authority.
April 1996	Pain Society Annual Conference. Pain Society, London.
May 1996	Medicine for Managers: Complementary Medicine. Institute of Health Services Management, London.
June 1996	Complementary Medicine Research and Development Workshop. Royal College of Physicians of London.
November 1996	Multiple Sclerosis Society National Conference, Birmingham.
November 1996	The Placebo Response. University of Westminster.
December 1996	Placebo and Nocebo Effects. Office of Alternative Medicine, National Institutes of Health, USA.
January 1997	Science-Based Complementary Medicine. Royal College of Physicians.
March 1997	Natural Therapies: Safe and Effective? Royal Pharmaceutical Society.
June 1997	Evidence Base of Complementary Medicine. Society of Pharmaceutical Medicine.
December 1997	Complementary Medicine Research. University of Bologna, Italy.
February 1998	Practicalities of Research in Complementary Medicine. Oxford University.
May 1998	Critical Appraisal. Oxford Spine Research Group.
May 1998	Why Use Placebos in Clinical Trials? Oxford University.
June 1998	Suitable Controls for use in Acupuncture Trials. Royal Marsden Hospital.
June 1998	Evidence Base of Complementary Medicine. Association for Quality in Healthcare / Royal Society of Medicine.
February 1999	Integration of Complementary Therapies. Royal Free Hospital and University College London Ethics Group
April 1999	Evidence-based Traditional Chinese Medicine: Acupuncture. Chinese University of Hong Kong (telemedicine conference)
July 1999	Cross-cultural issues in medicine. Royal College of Physicians.

September 1999	Complementary therapies on the National Health Service. Royal Society of Medicine.
May 2000	Methodology of Cancer Research. Center for Mind-Body Medicine
October 2000	Alternative Medicine? Complementary Medicine? Integrative Medicine? Maurer Foundation for Breast Health Education
November 2000	Botanical treatments for cancer: the possibilities and problems of polypharmacy. Weill Medical College of Cornell University
October 2001	Scientific lore versus folklore: alternative medicine. New School, New York
November 2001	Expert panel on complementary and alternative medicine research methodology. National Cancer Institute
March 2002	Complementary and alternative medicine for cancer. Columbia-Presbyterian Medical Center.
May 2002	Controversial aspects of clinical trials. American Society of Hypertension.
October 2002	Complementary and alternative medicine: Emerging trends in adjuvant therapy of breast cancer. Baylor-Charles A. Sammons Cancer Center.
March 2003	Development and funding of complementary and alternative medicine research. National Cancer Institute.
March 2003	Complementary and alternative medicine for cancer. Columbia-Presbyterian Medical Center.
May 2003	Complementary and Alternative Medicine. National Breast Cancer Coalition.
May 2003	A clinical trialist's approach to statistics: Why the rules don't matter. Weill Medical College of Cornell University
June 2003	Integrative oncology. Beth Israel, New York.
July 2003	Statistical analysis of clinical trials with baseline assessment. Albert Einstein Healthcare, Philadelphia.
September 2003	Complementary and Alternative Medicine. Adelphi New York Statewide Breast Cancer Hotline and Support Group, New York.
October 2003	Integrative Oncology. British Medical Acupuncture Society, London, UK.
December 2003	Lessons learned from a large randomized trial with a quality of life endpoint. Weill Medical College of Cornell University.
February 2004	Complementary and alternative medicine. New York SHARE.
March 2004	Sharing of data: scientific, ethical and regulatory concerns. International Biometric Society, ENAR.
November 2004	Research methodology for acupuncture research. Society for Integrative Oncology annual meeting, New York.
November 2004	Grand rounds: Integrative Oncology. Johns Hopkins CAM Center, Baltimore.
November 2004	Should we ban paper journals? Weill Medical College of Cornell University.
May 2005	Open Access: a researcher's view. Medical Librarians Association, San Antonio.
June 2005	Methodology for Phase I and II trials of novel therapies. Hematology and Oncology Pharmacists Association, San Diego.
June 2005	How to write a grant in complementary and alternative medicine. National Cancer Institute.
August 2005	Clinical trial design for research in cancer symptom control. Symptom Management, Palliative Care and Survivorship Program, University of California, San Francisco.

August 2005	Methodology of integrative medicine research. Osher Center for Integrative Medicine, University of California, San Francisco.
September 2005	Complementary and alternative medicine for cancer. Breast Examination Center of Harlem, New York.
November 2005	Methodology of Integrative Oncology Research. Society for Integrative Oncology annual meeting, San Diego.
March 2006	Integrative Oncology. CAM Expo East, New York.
October 2006	Experience counts: the surgeon as a variable in cancer control. Clinical Society of Genitourinary Surgeons, New York.
November 2006	How to write a grant in complementary and alternative medicine. National Cancer Institute.
December 2006	A learning curve for radical prostatectomy. Society for Urologic Oncology, Bethesda.
March 2007	Prediction and prostate cancer. Malecare, New York.
June 2007	Improving clinical trial design. The Center for Biomedical Continuing Education, Los Angeles.
September 2007	The surgical learning curve: radical prostatectomy as a model. Southern Illinois University, Springfield.
November 2007	Acupuncture in the care of the cancer patient. Society for Acupuncture Research, Baltimore, Maryland.
December 2007	The surgical learning curve: radical prostatectomy as a model. University of California San Francisco.
December 2007	Decision curve analysis. University of California San Francisco.
February 2008	The surgical learning curve: radical prostatectomy as a model. University Health Network, Toronto, Canada.
May 2008	Clinical utility of PSA velocity and PSA dynamics in localized prostate cancer, American Urologic Association Plenary Presentation, Orlando, Florida.
May 2008	Clinical trials, data sharing and supplemental materials. Society for Scholarly Publishing, Boston, Massachusetts.
August 2008	Should PSA screening be risk stratified? National Prostate Cancer Symposium, Melbourne, Australia.
August 2008	PSA velocity. National Prostate Cancer Symposium, Melbourne, Australia.
August 2008	Experience Counts – The effect of surgical experience on outcome of radical prostatectomy. National Prostate Cancer Symposium, Melbourne, Australia.
September 2008	Decision curve analysis. Cleveland Clinic, Cleveland, Ohio.
September 2008	Prediction and prostate cancer. US TOO prostate cancer support group, New York.
October 2008	Kallikreins to predict prostate cancer. P Mark, Turku, Finland.
February 2009	New prognostic markers: pitfalls in the path from research to clinical practice. Plenary session of American Society of Clinical Oncology Genitourinary Meeting.
March 2009	Decision curve analysis. International Biometric Society, ENAR.
May 2009	Long term prediction of prostate cancer: Special invited debate at the American Urologic Association.

June 2009	Should prostate cancer screening be risk stratified? St Thomas's Hospital, London, UK.
July 2009	Evaluating molecular markers for cancer. Cancer Epidemiology Group, King's College, London, UK.
October 2009	Evaluating complementary therapies for cancer. National Cancer Research Institute, UK.
October 2009	Decision curve analysis. Center for Statistics in Medicine, Oxford University, UK.
October 2009	How do we know whether a predictive model is of value? Drug Information Alliance, Bethesda.
November 2009	Decision curve analysis. Fred Hutchinson Cancer Research Center, Seattle, Washington.
April 2010	Decision curve analysis. University of South Florida, Tampa, Florida.
May 2010	Statistical evaluation of active surveillance. American Urologic Association invited educational session, San Francisco, California.
May 2010	Clinically-integrated randomized trials. Society for Clinical Trials annual meeting, Baltimore, Maryland.
July 2010	The surgical learning curve. University of California, Los Angeles. California.
September 2010	Active surveillance. Prostate Cancer Foundation, Washington, DC.
October 2010	Surgeon influences on outcome. British Association of Urologic Surgeons, London, UK.
December 2010	Statistical modelling of prostate cancer. CISNET, Washington, DC.
February 2011	Acupuncture Trialists' Collaboration. National Institutes of Health, Washington DC
April 2011	Traditional statistical evaluations of prediction models are uninformative. European School of Oncology, New York.
May 2011	The volume outcome relationship in urologic oncology. International Prostate Cancer Symposium, New York.
May 2011	Acupuncture Trialists' Collaboration. International Congress on Complementary Medicine Research, Chengdu, China.
May 2011	PSA velocity. Interactive Genitourinary Cancer Conference. Budapest, Hungary.
May 2011	Patient reported outcomes and surgeon feedback. Society of Urologic Oncology, Washington DC.
May 2011	Statistical evaluation of active surveillance. American Urologic Association invited educational session, Washington, DC.
June 2011	Clinically-integrated randomized trials. National Heart, Lung and Blood Institute, Washington, DC.
June 2011	Prostate cancer screening. American Association of Clinical Chemistry (webinar)
September 2011	Predicting the outcomes of the initial treatment of prostate cancer. PcBaSE, Sigtuna, Sweden.
September 2011	Biomarkers everywhere. How would we know if they are any good? Salerno University, Salerno, Italy.
September 2011	PSA: how an excellent marker turned into a public health fiasco (and how to turn it back). Universita' Vita Salute San Raffaele, Milan, Italy.

September 2011	The surgical learning curve (and what to do about it). Urological Research Society, Oxford, UK
September 2011	Biomarkers everywhere. How would we know if they are any good? Gray Institute for Radiation Oncology and Biology, Oxford University, Oxford, UK
November 2011	Randomized trials of surgical modifications. Society of Urologic Oncology. Washington DC.
January 2012	Decision-analytic evaluation of markers. Post-GWAS plenary meeting. Washington DC.
February 2012	Risk-stratifying screening for prostate cancer. Issues and Controversies in Prostate Care, Whistler, Canada
March 2012	Are nomograms useful for clinical practice? Interactive Genitourinary Cancer Conference. Prague, Czech Republic.
April 2012	How would we know whether a marker or model for prostate cancer were any good? Rajiv Ghandi Cancer Institute and Research Center, New Delhi, India
May 2012	Prostate cancer screening. Columbia University, New York, New York.
May 2012	Surgical databases. Society of Urologic Robotic Surgery, Atlanta, Georgia.
June 2012	PSA: how a great marker turned into a public health fiasco (and how to turn it back). Cancer Institute of New Jersey, New Brunswick, New Jersey
August 2012	PSA: how a great marker turned into a public health fiasco (and how to turn it back). University of California at Irvine, Irvine, California
September 2012	Clinical research data sharing practices and attitudes. Institute of Medicine, Washington DC
November 2012	Development of biomarkers into clinical practice, University of Turku, Turku, Finland
November 2012	Developing guidelines on PSA screening. CISNET, Bethesda, Maryland
November 2012	Surgeon variability and what to do about it. Cornell University, New York, New York.
February 2013	You can’t ignore your outcomes any longer. Excellence in Urology, Intermountain Health, Utah.
February 2013	PSA screening has been a public health disaster. Let’s keep doing it. University of Utah, Salt Lake City, Utah.
February 2013	PSA screening has been a public health disaster. Let’s keep doing it. University of South Florida, Tampa, Florida.
March 2013	The Acupuncture Trialists' Collaboration. University of Bristol, Bristol, UK
March 2013	PSA: how a great marker turned into a public health fiasco (and how to turn it back). University of Bristol, Bristol, UK.
April 2013	Surgeon variability, what to do about it and how this can transform clinical trials. Tufts University, Boston.
April 2013	PSA kinetics is a valuable prognostic tool in localised prostate cancer: Against. Interactive Genitourinary Cancer Conference. Rome, Italy.
June 2013	Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. Prostate Cancer Foundation, Santa Monica, California.
September 2013	PSA: how a great marker turned into a public health fiasco (and how to turn it back). McGill University, Montreal, Canada.
September 2013	Decision curve analysis. McGill University, Montreal, Canada.

October 2013	PSA: how a great marker turned into a public health fiasco (and how to turn it back). Royal Melbourne Hospital, Melbourne, Australia.
October 2013	The Acupuncture Trialists' Collaboration. Australian Physiotherapists' Association, Melbourne, Australia.
November 2013	PSA: how a great marker turned into a public health fiasco (and how to turn it back). Western Section of the American Urological Association, Monterey, California.
December 2013	The four-kallikrein marker panel. Society of Urologic Oncology, Washington, DC
March 2014	Early Detection of Prostate Cancer – Do the Benefits Outweigh the Consequences? NCCN Annual Conference, Hollywood, Florida
April 2014	Statistics in scientific papers. European Association of Urology Annual Conference, Stockholm, Sweden
May 2014	AMPLIO: Implementing surgeon performance feedback at MSKCC. Why a "bottom up" approach has been key. Michigan Urologic Surgery Improvement Collaborative, Ann Arbor, Michigan
June 2014	Six statistical slip ups (and how to avoid them). St. Barnabas Hospital, Livingston, New Jersey
August 2014	Serum markers for prostate cancer. International Symposium of Focal Therapy and Imagining of Prostate and Kidney Cancer. Pasadena, California.
August 2014	PSA and prostate cancer screening. Hospital Sirio-Libanes, Sao Paulo, Brazil.
October 2014	PSA and prostate cancer screening. JO Metcalfe Lectureship, University of Alberta, Canada.
November 2014	The Acupuncture Trialists' Collaboration. MD Anderson, Houston, Texas.
January 2015	Implementation of patient-reported outcomes in routine clinical practice. American College of Surgeons, Washington, DC.
February 2015	MSKCC web survey core and clinical research. Columbia University, New York.
February 2015	Use of PSA. Intermountain Health, Park City, Utah.
March 2015.	North American perspective on PSA screening. European Association of Urology, Madrid, Spain.
April 2015	Should we screen? If so, how? Urologic Society of Australia and New Zealand, Adelaide, Australia.
April 2015	Publishing surgeon outcomes. Urologic Society of Australia and New Zealand, Adelaide, Australia.
April 2015	Three lessons from MSKCC surgical quality assurance. New Zealand Prostate Registry, Auckland, New Zealand.

L. BIBLIOGRAPHY

Articles in peer-reviewed journals

1. **Vickers AJ**. Complementary medicine, intermediate medicine and the degree of intervention. Complementary Therapies in Medicine 1994;2(3):123-7.
2. **Vickers AJ**. Complementary therapies on the NHS: the NAHAT survey. Complementary Therapies in Medicine 1994;2:48-50.

3. **Vickers AJ**. Use of complementary therapies. British Medical Journal 1994 ;309:1161. PubMed PMID: 7987132; PubMed Central PMCID: PMC2541897.
4. **Vickers AJ**. Methodological issues in complementary and alternative medicine research. Journal of Alternative and Complementary Medicine 1996;2:515-24.
5. **Vickers AJ.** Regulating complementary medicine Researchers into complementary therapy do not have to "sacrifice their therapeutic integrity". British Medical Journal 1996;313:881-2. PubMed PMID: 8870592; PubMed Central PMCID: PMC2359079.
6. **Vickers AJ**. Complementary therapies in palliative care: the research evidence. European Journal of Palliative Care 1996;3:150-3.
7. **Vickers AJ**. Research, uncertainty and alternative medicine. Cancer Prevention International 1996;2:179-80.
8. **Vickers AJ.** Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. Journal of the Royal Society of Medicine 1996;89:303-11. PubMed PMID: 8758186; PubMed Central PMCID: PMC1295813.
9. **Vickers AJ**. A proposal for teaching critical thinking to students and practitioners of complementary medicine. Alternative Therapies in Health and Medicine 1997;3:57-62.
10. **Vickers AJ**, Smith C. Analysis of the evidence profile of the effectiveness of complementary therapies in asthma: a qualitative survey and systematic review. Complementary Therapies in Medicine 1997;5:202-9.
11. **Vickers AJ**. Yes, but how do we know it's true? Knowledge claims in massage and aromatherapy. Complementary Therapies in Nursing and Midwifery 1997;3:63-5.
12. Jawara N, Lewith G, Mullee M, **Vickers AJ**, Smith C. Homoepathy for delayed onset muscle soreness: a randomised, double-blind, placebo-controlled trial. British Journal Sports Med. 1997;31(4):304-7.
13. **Vickers AJ**, Cassileth B, Ernst E, Fisher P, Goldman P, Jonas W, Kang S, Lewith G, Schulz K, Silagy C. How should we research unconventional therapies? A panel report from the conference on Complementary and Alternative Medicine Research Methodology, National Institutes of Health. International Journal of Technology Assessment in Health Care 1997;13:111-21.
14. **Vickers AJ,** Fisher P, Smith C, Wyllie SE, Lewith GT. Homoeopathy for delayed-onset muscle soreness: a randomised, double-blind, placebo-controlled trial. British Journal of Sports Medicine 1997;31:304-7. PubMed PMID: 9429007; PubMed Central PMCID: PMC1332564.
15. **Vickers AJ**, Harland R, Goyal N, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clinical Trials 1998;19:159-66.
16. Jenkins M, **Vickers AJ**. Poor reliability of IgE / IgG4 antibody testing as a diagnostic tool in food intolerance. Clinical and Experimental Allergy 1998;28:1526-9.
17. **Vickers AJ**. Bibliometric analysis of randomised controlled trials in complementary medicine. Complementary Therapies in Medicine 1998;6:185-9.
18. **Vickers AJ**, Fisher P, Smith C, Wyllie SE, Rees RW. Arnica 30x is ineffective for muscle soreness after long-distance running: a randomised, double-blind, placebo-controlled trial. Clinical Journal of Pain 1998;14:227-31.
19. **Vickers AJ**. Against individualistic medicine. Complementary Therapies in Medicine 1998;6:61-3.

20. de Craen AJM , **Vickers AJ**, Tijssen JGP , Kleijnen J. The number-needed-to-treat and placebo-controlled trials. Lancet 1998;351:310.
21. **Vickers AJ**. Against mind-body medicine. Complementary Therapies in Medicine 1998;6:111-4.
22. **Vickers AJ**, Ohlsson A, Lacy JB, Horsley A. Massage therapy for premature and/or low birth-weight infants to improve weight gain and/or to decrease hospital length of stay. (Cochrane Review) In: The Cochrane Library, Issue 3. Oxford: Update Software; 1998.
23. **Vickers AJ**, Rees RW, Robin A. Advice given by health food shops: is it clinically safe? Journal of the Royal College of Physicians of London 1998;32:426-8.
24. **Vickers AJ**. Evidence-based medicine and complementary medicine. Evidence-Based Medicine 1998;3:168-9.
25. Ezzo J, Berman BM, **Vickers AJ**, Linde K. Complementary medicine, evidence-based medicine and the Cochrane Collaboration. Journal of the American Medical Association 1998;280:1628-30.
26. **Vickers AJ**. Independent replication of pre-clinical research in homoeopathy: a systematic review. Forschende Komplementärmedizin 1999;6:311-20.
27. **Vickers AJ**. Evidence-based medicine and complementary medicine. ACP Journal Club. 1999;130(2):A13-4.
28. **Vickers AJ**, Rees RW, Zollman CE, Smith C, Ellis N. Acupuncture for migraine and headache in primary care: a protocol for a pragmatic, randomised trial. Complementary Therapies in Medicine 1999;7:3-18.
29. Harrison H, Fixsen A, **Vickers AJ**. A randomized comparison of homoeopathic and standard care for the treatment of glue ear in children. Complementary Therapies in Medicine 1999;7(3):132-5.
30. Zollman CE, **Vickers AJ**. ABC of complementary medicine: What is complementary medicine?. British Medical Journal 1999;319:693-6.
31. Zollman CE, **Vickers AJ**. ABC of complementary medicine: Users and practitioners of complementary medicine. British Medical Journal 1999;319:836-8. PubMed PMID: 10496832; PubMed Central PMCID: PMC1116666.
32. Zollman CE, **Vickers AJ**. ABC of complementary medicine: Complementary medicine in conventional practice. British Medical Journal 1999;319:901-4. PubMed PMID: 10506051; PubMed Central PMCID: PMC1116726.
33. **Vickers AJ,** Zollman CE. ABC of complementary medicine: Acupuncture. British Medical Journal 1999;319:973-6. PubMed PMID: 10514163; PubMed Central PMCID: PMC1116804.
34. **Vickers AJ,** Zollman CE. ABC of complementary medicine: Herbal medicine. British Medical Journal 1999;319:1050-3. PubMed PMID: 10521203; PubMed Central PMCID: PMC1116847.
35. **Vickers AJ,** Zollman CE. ABC of complementary medicine: Homoeopathy. British Medical Journal 1999;319:1115-8. PubMed PMID: 10531108; PubMed Central PMCID: PMC1116906.
36. **Vickers AJ,** Zollman CE. ABC of complementary medicine: The manipulative therapies: osteopathy and chiropractic. British Medical Journal 1999;319:1176-9. PubMed PMID: 10541511; PubMed Central PMCID: PMC1116959.

37. **Vickers AJ,** Zollman CE. ABC of complementary medicine: Massage therapies. British Medical Journal 1999;319:1254-7. PubMed PMID: 10550095; PubMed Central PMCID: PMC1117024.
38. **Vickers AJ**, Zollman CE. ABC of complementary medicine: Hypnosis and relaxation therapies. British Medical Journal 1999;319:1346-9. PubMed Central PMCID: PMC1117083.
39. Zollman CE, **Vickers AJ**. ABC of complementary medicine: Unconventional approaches to nutritional medicine. British Medical Journal 1999;319:1419-22. PubMed PMID: 10574865; PubMed Central PMCID: PMC1117146.
40. Zollman CE, **Vickers AJ**. ABC of complementary medicine: Complementary medicine and the patient. British Medical Journal 1999;319:1486-9. PubMed PMID: 10582937; PubMed Central PMCID: PMC1117208.
41. Zollman CE, **Vickers AJ**. ABC of complementary medicine: Complementary medicine and the doctor. British Medical Journal 1999;319:1558-61. PubMed PMID: 10591724; PubMed Central PMCID: PMC1117269.
42. Melchart D, Linde K, Fischer P, White A, Allais G, **Vickers AJ**, Berman B. Acupuncture for chronic headache: a systematic review of randomized controlled trials. Cephalalgia. 1999;19:779-86.
43. **Vickers AJ**. Comparison of an ordinal and a continuous measure of muscle soreness. International Journal of Technology Assessment in Health Care 1999;15:709-16.
44. **Vickers AJ**, Smith C. Oscillococcinum in the prevention and treatment of influenza and influenza-like syndromes. (Cochrane Review) In: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.
45. **Vickers AJ**, Smith C. Incorporating data from dissertations in systematic reviews. International Journal of Technology Assessment in Health Care 2000;16(2):711-3.
46. **Vickers AJ**. Recent advances in complementary medicine. British Medical Journal 2000:321(7262):683-6. PubMed PMID: 10987776; PubMed Central PMCID: PMC1118559.
47. **Vickers AJ**. de Craen AJM. Why use placebos in clinical trials? A narrative review of the methodological literature. Journal of Clinical Epidemiology 2000;53(2):157-161.
48. **Vickers AJ.** Why aromatherapy works (even if it doesn't) and why we need less research. British Journal of General Practice 2000;50:444-5. PubMed PMID: 10962780; PubMed Central PMCID: PMC1313720.
49. Rees RW, Feigel I, **Vickers AJ**, Zollman C, McGurk R, Smith C. Prevalence of complementary therapy use by women with breast cancer: a population-based survey. European Journal of Cancer 2000;36(11):1359-64.
50. **Vickers AJ**, Christos P. Bezwoda: evidence of fabrication in original paper. Journal of Clinical Oncology 2000;18(15):2933.
51. Cassileth BR, **Vickers AJ**. Cancer, unproven therapies and magic: the article reviewed. Oncology 2000;14(9):1358-9.
52. **Vickers AJ**. On breakfast and randomized trials. British Medical Journal 2001;322:85
53. **Vickers AJ**, Cassileth BR. A review of unconventional therapies used for treatment of cancer and cancer-related symptoms. Lancet Oncology 2001;2:226-32.
54. **Vickers AJ.** Message to complementary and alternative medicine: evidence is a better friend than power. BiomedCentral Complementary and Alternative Medicine 2001, 1:1. PubMed PMID: 11346455; PubMed Central PMCID: PMC32159.

55. **Vickers AJ**, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow-up measurements. British Medical Journal 2001;323:1123-1124. PubMed PMID: 11701584; PubMed Central PMCID: PMC1121605.
56. Linde K, **Vickers AJ**, Hondras M, ter Riet G, Thormaehlen J, Berman B, Melchart D. Systematic reviews of complementary therapies. Part 1: Acupuncture. BiomedCentral Complementary and Alternative Medicine 2001;1:3. PubMed PMID: 11513758; PubMed Central PMCID: PMC37539.
57. Linde K, ter Riet G, Hondras M, **Vickers AJ**, Saller R, Melchart D. Systematic reviews of complementary therapies. Part 2: Herbal Medicine. BiomedCentral Complementary and Alternative Medicine 2001;1:5. PubMed PMID: 11518548; PubMed Central PMCID: PMC37540.
58. **Vickers AJ**. Time course of muscle soreness following different types of exercise. BiomedCentral Musculoskeletal Disorders 2001;2(1):5. PubMed PMID: 11701094; PubMed Central PMCID: PMC59671.
59. Cassileth BR, Schraub S, Robinson E, **Vickers AJ**. Alternative medicine use worldwide: The International Union Against Cancer survey. Cancer 2001;91(7):1390-3.
60. **Vickers AJ**. Survey of complementary and alternative medicine use by cancer patients in Hawaii: the article reviewed. Oncology 2001;15(10):1272-4.
61. **Vickers AJ.** The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. Biomed Central Medical Research Methodology 2001;1:6. PubMed PMID: 11459516; PubMed Central PMCID: PMC34605.
62. **Vickers AJ.** Acupuncture for treatment for chronic neck pain. Reanalysis of data suggests that effect is not a placebo effect. BMJ 2001 1:323:1306-7. PubMed PMID: 11764758; PubMed Central PMCID: PMC1121759.
63. **Vickers AJ.** Widespread body pain and mortality: Theories that psychological states cause cancer should be rejected. British Medical Journal 2002;324:300. PubMed PMID: 11823375; PubMed Central PMCID: PMC1122214.
64. Irnich D, Behrens N, Gleditsch JM, Stör W, Schrieber MA, Schöps P, **Vickers AJ**, Beyer A. Immediate effects of dry needling and acupuncture at distant points in chronic neck pain: results of a randomized, double-blind, sham-controlled crossover trial. Pain 2002;99(1-2):83-9.
65. Cheung NK, Modak S, **Vickers AJ**. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.Cancer Immunology and Immunotherapy 2002;51(10):557-64.
66. **Vickers AJ**. Placebo controls in randomized trials of acupuncture. Evaluation and the Health Professions 2002;25(4):421-35.
67. **Vickers AJ**. Botanical medicines for the treatment of cancer: rationale, overview of current data and methodological considerations for Phase I and II trials. Cancer Investigation 2002;20(7-8):1069-79.
68. Risberg T, **Vickers AJ**, Bremnes RM, Wist EA, Kaasa S, Cassileth BR. Does alternative medicine use predict survival in cancer? European Journal of Cancer 2003;39: 372–377.
69. Cassileth BR, **Vickers AJ**. Localized prostate cancer: Complementary and alternative therapies. Urologic Clinics of North America 2003;30:369-76.
70. **Vickers AJ**. Underpowering in randomized trials reporting a sample size calculation. Journal of Clinical Epidemiology 2003;56(8):717-20.

71. **Vickers AJ**. How many repeated measures in repeated measures designs? Statistical issues for comparative trials. BiomedCentral Medical Research Methodology 2003;3:22.
72. **Vickers AJ**, McCarney R. Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year. Controlled Clinical Trials 2003;24(6):731-5.
73. Cassileth BR, **Vickers AJ**. Soy: an anticancer agent in wide use despite some troubling data. Cancer Invest. 2003;21(5):817-8.
74. Cassileth BR, **Vickers AJ**, Magill LA. Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial. Cancer 2003;98(12):2723-2729.
75. Wonderling D, **Vickers AJ**, Grieve R, McCarney R. Cost-effectiveness analysis of a randomised trial of acupuncture for migraine and chronic tension headache in primary care. British Medical Journal 2004;328:747-9.
76. **Vickers AJ**, Rees RW, Zollman CE, McCarney R, Smith C, Ellis N, Fisher P, Van Haselen R. Acupuncture for chronic headache in primary care: a large, pragmatic, randomised trial. British Medical Journal 2004;328:744-7.
77. **Vickers AJ**. Statistical considerations for use of composite health-related quality-of-life scores in randomized trials. Quality of Life Research 2004;13 :717 –723.
78. **Vickers AJ**. Cassileth BR. Strauss D. Acupuncture for post-chemotherapy fatigue: a Phase II study. Journal of Clinical Oncology 2004;22(9):1731-5.
79. Kattan MW, **Vickers AJ**. Incorporating predictions of individual patient risk in clinical trials. Urologic Oncology 2004;22(4):348-52.
80. **Vickers AJ**. Statistical reanalysis of four recent randomized trials of acupuncture for pain using analysis of covariance. Clinical Journal of Pain 2004;20(5):319-23.
81. Cassileth BR, **Vickers AJ**. Massage therapy for symptom control: Outcome study at a major cancer center. Journal of Pain and Symptom Management 2004;28:244-9.
82. Lassman AB, Dai C, Fuller GN, **Vickers AJ**, Holland EC. Overexpression of c-Myc promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuronal and Glial Biology 2004;1:157-163.
83. **Vickers AJ**, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, Fisher P, Van Haselen R, Wonderling D, Grieve R. Acupuncture of chronic headache disorders in primary care: randomised controlled trial and economic analysis. Health Technology Assessment. 2004;8(48):1-35.
84. **Vickers AJ**. Alternative cancer cures: "unproven" or "disproven"? CA: A Cancer Journal for Clinicians. 2004;54(2):110-8.
85. Modak S, Koehne G, **Vickers AJ**, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1→3), (1→4)-D-β-glucan. Leukemia Research 2005;29:679–83.
86. Tao Y, Klause A, **Vickers AJ**, Bae K, Ellis M. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. Journal of Steroid Biochemistry and Molecular Biology 2005; 95:91-5.
87. **Vickers AJ**. Analysis of variance is easily misapplied in the analysis of randomized trials: a critique and discussion of alternative statistical approaches. Psychosomatic Medicine 2005;67:652-5.

88. Secin FP, Karanikolas N, Touijer AK, Salamanca JI, **Vickers AJ**, Guillonneau B. Anatomy of accessory pudendal arteries in laparoscopic radical prostatectomy. Journal of Urology 2005;174(2):523-6.
89. **Vickers AJ**. How to interpret data from randomized trials. The Scandinavian prostatectomy study illustrates two common errors. Nature Clinical Practice Urology 2005;Sep;2(9):404-5.
90. Cassileth BR, **Vickers AJ**. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. Journal of Clinical Oncology 2005;23:2590-2592.
91. Ezzo JM, **Vickers AJ**, Richardson MA, Allen C, Dibble SL, Issell BF, Lao L, Pearl M, Ramirez G, Roscoe JA, Shen J, Shivnan JC, Streitberger K, Treish I, Zhang G. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting: a systematic review. Journal of Clinical Oncology 2005; 23(28):7188-98.
92. **Vickers AJ**, Feinstein MB, Deng GE, Cassileth BR Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial (ISRCTN89462491). BMC Palliative Medicine 2005;4(1):5.
93. Secin FP, Karanikolas N, Kuroiwa K, **Vickers AJ**, Touijer K, Guillonneau B. Positive surgical margins and accessory pudendal artery preservation during laparoscopic radical prostatectomy. European Urology 2005; 48(5):786-92.
94. **Vickers AJ**. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. BMC Medical Research Methodology 2005;5:35.
95. **Vickers AJ**, Bianco FJ, Boorjian S, Scardino P, Eastham JA. Does delay between diagnosis and radical prostatectomy increase the risk of cancer recurrence? Cancer 2006;106(3):576-80.
96. Steuber T, **Vickers AJ**, Haese A, Becker C, Pettersson K, Chun FK-H, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H. Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 and free prostate-specific antigen (PSA) in men with moderate PSA-elevation in serum. International Journal of Cancer 2006;118(5):1234-40.
97. **Vickers AJ**, Kuo J, Cassileth BR. Unconventional anticancer agents: a systematic review of clinical trials. Journal of Clinical Oncology 2006;24(1):136-40.
98. DiBlasio CJ, Masterson TA, Fearn PA, Seo HS, Rabbani F, **Vickers AJ,** Eastham JA, Scardino PT. The association between total and positive lymph node counts, disease progression in clinically localized prostate cancer. Journal of Urology 2006;175(4):1320-4.
99. Khokhar A, **Vickers AJ**, Moore MS, Mironov S, Stover DE, Feinstein MB. Significance of non-calcified pulmonary nodules among patients with extra-pulmonary cancers. Thorax 2006;61(4):331-6. PubMed PMID: 16467070; PubMed Central PMCID: PMC2104619.
100. Ezzo JM, Richardson MA, **Vickers AJ**, Allen C, Dibble SL, Issell BF, Lao L, Pearl M, Ramirez G, Roscoe JA, Shen J, Shivnan JC, Streitberger K, Treish I, Zhang G. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. Cochrane Database of Systematic Reviews 2006;(2):CD002285.

101. Dash A, **Vickers AJ**, Schacter L, Bach A, Snyder M, Russo P. Elective partial versus elective radical nephrectomy for clear cell renal cell carcinoma 4-7 cm in size. BJU International 2006; 97(5):939-45.
102. **Vickers AJ**, Rusch VW, Malhotra VT, Downey RJ, Cassileth BR. Acupuncture is a feasible treatment for post-thoracotomy pain: Results of a prospective clinical trial. BMC Anaesthesia 2006;6:5.
103. **Vickers AJ.** Whose data set is it anyway? Sharing raw data from randomized trials. Trials 2006:7:15.
104. **Vickers AJ**. How to design a Phase I trial of an anticancer botanical. Journal of the Society for Integrative Oncology 2006;4:46-51.
105. Raj GV, Bochner BH, **Vickers AJ**, Teper E, Lin O, Donat SM, Herr H, Dalbagni G. Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract. Journal of Urology 2006;175(6):2038-41.
106. Carver BS, Bianco FJ, Shavegan B, **Vickers AJ**, Motzer RJ, Bosl GJ, Sheinfeld J. Predicting teratoma in the retroperitoneum for men undergoing post-chemotherapy retroperitoneal lymph node dissection. Journal of Urology 2006;176(1):100-4.
107. Cheung IY, **Vickers AJ**, Cheung NK. Sialyltransferase STX (ST8SiaII): a novel molecular marker of neuroblastoma. International Journal of Cancer 2006;119(1):152-6.
108. Su YB, **Vickers AJ**, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP, Serio AM, Barrison LB, Bosl GJ, Pfister DG. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor (G-CSF) during post-operative radiotherapy for squamous head and neck cancer. Cancer Journal 2006;12(3):182-8.
109. **Vickers AJ**. How to measure quality of life in integrative oncology research. Journal of the Society for Integrative Oncology 2006;4:100-103.
110. Cheung NKV, **Vickers AJ**, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. Journal of Clinical Oncology 2006;24(18):2885-90.
111. Donohue JF, Bianco FJ, Kuroiwa K, **Vickers AJ**, Wheeler TM, Scardino PT, Reuter V, Eastham JA. Poorly differentiated prostate cancer treated by radical prostatectomy: Long-term outcome and incidence of downgrading. Journal of Urology 2006; 176(3):991-5.
112. Elkin EB, **Vickers AJ**, Kattan MW. Primer: using decision analysis to improve clinical decision making in urology. Nature Clinical Practice Urology 2006:3:439-448.
113. **Vickers AJ.** Multiple assessment in quality of life trials: how many questionnaires? How often should they be given? Journal of the Society for Integrative Oncology 2006;4:135-139.
114. Yossepowitch O, Eggener SE, Serio A, Huang WC, Snyder ME, **Vickers AJ**, Russo P. Temporary renal ischemia during nephron-sparing surgery is associated with short-term but not long-term impairment of renal function. Journal of Urology 2006;176(4):1339-43
115. Huang WC, Levey AS, Serio AM, Snyder M, **Vickers AJ**, Raj G, Scardino PT, Russo P. Chronic kidney disease following nephrectomy in patients with renal cortical tumors. Lancet Oncology 2006;7(9):735-40.
116. Dash A, Galsky MD, **Vickers AJ**, Serio AM, Koppie TM, Dalbagni G, Bochner BH. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006; 107(3):506-13.

117. Touijer K, Kuroiwa K, **Vickers AJ**, Reuter VE, Guillonneau B. Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. European Urology 2006;49(5):853-8. PubMed Central PMCID: PMC1951513.
118. Secin FP, Bianco FJ, **Vickers AJ**, Fearn P, Scardino PT, Eastham JA. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. Cancer 2006;106(11):2369-75.
119. Sandhu JS, **Vickers AJ**, Bochner B, Donat SM, Herr HW, Dalbagni G. Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU International 2006;98(1):59-62.
120. Pettus JA, Eggener SE, Shabsigh A, Yanke B, Snyder ME, Serio A, **Vickers A**, Russo P, Donat SM. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006;68(5):988-92.
121. **Vickers AJ**. How to randomize. Journal of the Society for Integrative Oncology 2006;4(4):194-8.
122. **Vickers AJ**, Kramer BS, Baker SG. Selecting patients for randomized trials: a systematic approach based on risk group. Trials 2006; 7(1):30.
123. Raj GV, Bochner BH, Serio AM, **Vickers AJ**, Donat SM, Herr H, Lin O, Dalbagni G. Natural history of patients with positive urinary cytologies after radical cystectomy. Journal of Urology 2006;176(5):2000-5.
124. **Vickers AJ**, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Medical Decision Making 2006;26(6):565-74.
125. Koppie TM, **Vickers AJ**, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: Can we establish a minimum number of lymph nodes that should be removed? Cancer 2006;107(10):2368-74.
126. Raj GV, Tal R, **Vickers AJ**, Bochner BH, Serio A, Donat SM, Herr H, Olgac S, Dalbagni G. Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer. 2006;107(9):2167-72.
127. Secin FP, Serio A, Bianco FJ Jr, Karanikolas NT, Kuroiwa K, **Vickers A**, Touijer K, Guillonneau B. Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer. European Urology. 2007;51(3):764-71.
128. **Vickers AJ**. How to improve accrual to clinical trials of symptom control 1: recruitment strategies. Journal of the Society for Integrative Oncology 2007;5(1):38-42.
129. **Vickers AJ**, Ballen V, Scher HI. Setting the bar in Phase II trials: the use of historical data for determining "go / no go" decision for definitive phase III testing. Clinical Cancer Research 2007;13(3):972-6.
130. Steuber T, **Vickers AJ**, Serio AM, Vaisanen V, Haese A, Danø K, Pettersson K, Eastham JA, Scardino PT, Huland H, Lilja H. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clinical Chemistry 2007;53(2):233-40.
131. Lilja H, **Vickers AJ**, Scardino P. Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer. Journal of Clinical Oncology 2007;25(4):347-8.

132. Russo P, Snyder M, **Vickers A**, Kondagunta V, Motzer R. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. TSW Urology 2007;7:768-78.
133. Secin FP, Koppie TM, Salamanca JI, Bokhari S, Raj GV, Olgac S, Serio A, **Vickers AJ**, Bochner BH. An evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. International Journal of Urology. 2007;14(1):26-32.
134. Steuber T, **Vickers AJ**, Haese A, Danø K, Høyer-Hansen G, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. International Journal of Cancer 2007;120(7):1499-504.
135. Touijer K, Kuroiwa K, Eastham JA, **Vickers A**, Reuter VE, Scardino PT, Guillonneau B. Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy. European Urology. 2007;52(4):1090-6.
136. **Vickers AJ**. How to improve accrual to clinical trials of symptom control 2: design issues. Journal of the Society for Integrative Oncology 2007;5(2):61-4.
137. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, **Vickers AJ**, Dalbagni G. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. Journal of Urology. 2007;177(4):1283-6.
138. Cheung IY, Feng Y, **Vickers A**, Gerald W, Cheung NK. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. Journal of Molecular Diagnostics. 2007;9(2):237-41. PubMed PMID: 17384216; PubMed Central PMCID: PMC1867438
139. Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, **Vickers AJ**, Berglund G. Long-term prediction of prostate cancer in a large, representative Swedish cohort: prostate kallikreins measured at age 44-50 predict prostate cancer up to 25 years before diagnosis. Journal of Clinical Oncology 2007;25(4):431-6.
140. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, **Vickers AJ**, Lilja H, Reuter VE, Scardino PT. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clinical Cancer Research. 2007;13(14):4130-8.
141. **Vickers AJ,** Kattan MW, Sargent D. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials 2007, 8:14.
142. Eggener SE, Yossepowitch O, Serio AM, **Vickers AJ**, Scardino PT, Eastham JA. Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy. Urology. 2007;69(6):1128-33.
143. **Vickers AJ**. Which botanicals or other unconventional anticancer agents should we take to clinical trial? Journal of the Society for Integrative Oncology 2007;5(3):125-9.
144. **Vickers AJ**, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. The surgical learning curve for prostate cancer control after radical prostatectomy. Journal of the National Cancer Institute 2007;99: 1171 – 7.
145. **Vickers AJ**, Ulmert D, Serio AM, Björk T, Scardino PT, Eastham JA, Berglund G, Lilja H. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. International Journal of Cancer. 2007;121(10):2212-7.

146. Endres HG, Böwing G, Diener HC, Lange S, Maier C, Molsberger A, Zenz M, **Vickers AJ**, Tegenthoff M. Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial. Journal of Headache Pain. 2007; 8(5):306-14.
147. Touijer K, Kuroiwa K, Eastham JA, **Vickers A**, Reuter VE, Scardino PT, Guillonneau B. Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy. European Urology. 2007; 52(4):1090-6.
148. Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, **Vickers AJ**, Jumbelic M, Threatte G, Korets R, Lilja H, de la Roza G. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. Journal of the National Cancer Institute. 2007; 99(19):1484-9.
149. Eastham JA, Kuroiwa K, Ohori M, Serio AM, Gorbonos A, Maru N, **Vickers AJ**, Slawin KM, Wheeler TM, Reuter VE, Scardino PT. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology. 2007; 70(5):965-9.
150. **Vickers A**. How should we define patients who are at high risk of death from prostate cancer? Nature Clinical Practice Urology. 2007; 4(12):646-7.
151. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, **Vickers AJ**, Sheinfeld J. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. Journal of Clinical Oncology. 2007; 25(35):5603-8.
152. Deng G, **Vickers A**, Yeung S, Cassileth B. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. Journal of Clinical Oncology. 2007; 10;25(35):5584-90.
153. Tran W, Serio AM, Raj GV, Dalbagni G, **Vickers AJ**, Bochner BH, Herr H, Donat SM. Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. Journal of Urology. 2008; 179(1):96-100.
154. Klein EA, Kattan M, Stephenson A, **Vickers A**. How many lymphadenectomies does it take to cure one patient? European Urology. 2008; 53(1):13-5.
155. Secin FP, Jiborn T, Bjartell AS, Fournier G, Salomon L, Abbou CC, Haber GP, Gill IS, Crocitto LE, Nelson RA, Cansino Alcaide JR, Martínez-Piñeiro L, Cohen MS, Tuerk I, Schulman C, Gianduzzo T, Eden C, Baumgartner R, Smith JA, Entezari K, van Velthoven R, Janestschek G, Serio AM, **Vickers AJ**, Touijer K, Guillonneau B. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. European Urology 2008;53(1):134-45.
156. Klein EA, Bianco FJ, Serio AM, Eastham JA, Kattan MW, Pontes JE, **Vickers AJ**, Scardino PT. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. Journal of Urology 2008;179(6):2212-6.
157. Koppie TM, Serio AM, **Vickers AJ**, Vora K, Dalbagni G, Donat SM, Herr HW, Bochner BH. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112(11):2384-92.
158. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, **Vickers AJ**, Gerald WL, Abate-Shen C. Activator protein-1

transcription factors are associated with progression and recurrence of prostate cancer. Cancer Research 2008;68(7):2132-44.

159. Touijer K, Eastham JA, Secin FP, Romero Otero J, Serio A, Stasi J, Sanchez-Salas R, **Vickers A**, Reuter VE, Scardino PT, Guillonneau B. Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. Journal of Urology. 2008;179(5):1811-7.
160. Lilja H, Ulmert D, **Vickers AJ**. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews Cancer. 2008;8(4):268-78.
161. **Vickers AJ**, Jang K, Sargent D, Lilja H, Kattan MW. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer. 2008;112(8):1862-8.
162. **Vickers AJ**, Cassileth BR. Living proof and the pseudoscience of alternative cancer treatments. Journal of the Society of Integrative Oncology. 2008;6(1):37-40.
163. Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, **Vickers AJ**, Lilja H. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Journal of Clinical Oncology. 2008;26(6):835-41.
164. Ulmert D, Cronin AM, Björk T, O'Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, **Vickers AJ**, Lilja H. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Medicine. 2008;6:6.
165. Masterson TA, Serio AM, Mulhall JP, **Vickers AJ**, Eastham JA. Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function. BJU International. 2008;101(10):1217-22.
166. **Vickers AJ**, Bianco FJ, Gonen M, Cronin AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. European Urology. 2008;53(5):960-6.
167. Steyerberg EW, **Vickers AJ**. Decision curve analysis: a discussion. Medical Decision Making 2008;28(1):146-9.
168. **Vickers AJ**. Basic introduction to research: how not to do research. Journal of the Society of Integrative Oncology. 2008;6(2):82-5.
169. **Vickers AJ**. Do we want more cancer patients on clinical trials If so, what are the barriers to greater accrual? Trials. 2008;9:31.
170. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, **Vickers A**, Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? Journal of the National Cancer Institute. 2008;100(11):773-83.
171. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, **Vickers A**, Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? Journal of the National Cancer Institute. 2008;100(11):773-783.
172. Park J, Linde K, Manheimer E, Molsberger A, Sherman K, Smith C, Sung J, **Vickers A**, Schnyer R. The status and future of acupuncture clinical research. Journal of Alternative and Complementary Medicine. 2008;14(7):871-881. PubMed PMID: 18803496; PubMed Central PMCID: PMC3155101.

173. Ragupathi G, Yeung KS, Leung PC, Lee M, Lau CB, **Vickers A**, Hood C, Deng G, Cheung NK, Cassileth B, Livingston P. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine. 2008;26(37):4860-4865. PubMed PMID: 18640165; PubMed Central PMCID: PMC2565601.
174. Deng G, Rusch V, **Vickers A**, Malhotra V, Ginex P, Downey R, Bains M, Park B, Rizk N, Flores R, Yeung S, Cassileth B. Randomized controlled trial of a special acupuncture technique for pain after thoracotomy. Journal of Thoracic and Cardiovascular Surgery. 2008;136(6):1464-1469.
175. **Vickers AJ**, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Medcine. 2008;6:19.
176. **Vickers AJ**, Basch E, Kattan MW. Against diagnosis. Annals of Internal Medicine. 2008;149(3):200-203.
177. **Vickers AJ**. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. European Urology 2008;54(4):802-803.
178. Cronin AM, **Vickers AJ**. Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: a simulation study. BMC Medical Research Methodology. 2008;8:75.
179. **Vickers AJ,** Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Medical Informatics and Decision Making 2008;8:53.
180. Deng G, Rusch V, **Vickers A**, Malhotra V, Ginex P, Downey R, Bains M, Park B, Rizk N, Flores R, Yeung S, Cassiletha B. Randomized controlled trial of a special acupuncture technique for pain after thoracotomy. The Journal of Thoracic and Cardiovascular Surgery. 2008;136(6):1464-9. PubMed PMID: 19114190; PubMed Central PMCID: PMC2633643.
181. **Vickers AJ**. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. The American Statistician. 2008;62(4):314-320.
182. Savage CJ, **Vickers AJ**. Empirical study of data sharing by authors publishing in PLoS journals. Public Library of Science One. 2009;4(9):e7078.
183. Baker SG, Cook NR, **Vickers A**, Kramer BS. Using relative utility curves to evaluate risk prediction. Journal Of The Royal Statistical Society Series A. 2009;172(4):729-48. PubMed PMID: 20069131; PubMed Central PMCID: PMC2804257.
184. Linde K, Allais G, Brinkhaus B, Manheimer E, **Vickers A**, White AR. Acupuncture for migraine prophylaxis. Cochrane Database of Systematic Reviews. 2009;(1):CD001218. PubMed PMID: 19160193; PubMed Central PMCID: PMC3099267.
185. Linde K, Allais G, Brinkhaus B, Manheimer E, **Vickers A**, White AR. Acupuncture for tension-type headache. Cochrane Database of Systematic Reviews. 2009;1:CD007587. PubMed PMID: 19160338; PubMed Central PMCID: PMC3099266.
186. **Vickers AJ**. Phase II designs for anticancer botanicals and supplements. Journal of the Society for Integrative Oncology. 2009;7(1):35-40.
187. **Vickers AJ**, Lilja H. Cutpoints in clinical chemistry: time for fundamental reassessment. Clinical Chemistry. 2009;55(1):15-7.

188. Eggener SE, **Vickers AJ**, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ, Jr., Scardino PT. Comparison of models to predict clinical failure after radical prostatectomy. Cancer. 2009;115(2):303-10.
189. **Vickers AJ**, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. Journal of Clinical Oncology. 2009;27(3):398-403.
190. **Vickers AJ**, Elkin EB, Steyerberg E. Net reclassification improvement and decision theory. Statistics in Medicine. 2009;28(3):525-6.
191. Secin FP, Bianco FJ, Cronin A, Eastham JA, Scardino PT, Guillonneau B, **Vickers AJ**. Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria. Journal of Urology. 2009;181(2):609-13.
192. Wenske S, Korets R, Cronin AM, **Vickers AJ**, Fleisher M, Scher HI, Pettersson K, Guillonneau B, Scardino PT, Eastham JA, Lilja H. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. International Journal of Cancer. 2009;124(3):659-63.
193. Thompson RH, Kaag M, **Vickers A**, Kundu S, Bernstein M, Lowrance W, Galvin D, Dalbagni G, Touijer K, Russo P. Contemporary use of partial nephrectomy at a tertiary care center in the United States. Journal of Urology. 2009;181(3):993-7. PubMed PMID: 19150552; PubMed Central PMCID: PMC2724261.
194. Kattan MW, **Vickers AJ**, Yu C, Bianco FJ, Cronin AM, Eastham JA, Klein EA, Reuther AM, Edson Pontes J, Scardino PT. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer. 2009;115(5):1005-10.
195. **Vickers AJ**, Scardino PT. The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost. Trials. 2009;10:14.
196. Berglund RK, Stephenson AJ, Cronin AM, **Vickers AJ**, Eastham JA, Klein EA, Guillonneau BD. Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram. Urology. 2009;73(5):1098-103.
197. **Vickers AJ**, Savage CJ, Hruza M, Tuerk I, Koenig P, Martinez-Pineiro L, Janetschek G, Guillonneau B. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncology. 2009;10(5):475-80.
198. Touijer K, Secin FP, Cronin AM, Katz D, Bianco F, Vora K, Reuter V, **Vickers AJ**, Guillonneau B. Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. European Urology. 2009;55(5):1014-9.
199. **Vickers AJ**, Lilja H. Prostate cancer: Estimating the benefits of PSA screening. Nature Reviews Urology. 2009;6(6):301-3.
200. **Vickers AJ**, Elkin EB, Peele PB, Dickler M, Siminoff LA. Long-term health outcomes of a decision aid: data from a randomized trial of adjuvant! In women with localized breast cancer. Medical Decision Making. 2009;29(4):461-7.
201. O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, **Vickers AJ**, Lilja H. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. Journal of Clinical Oncology. 2009;27(22):3591-7.

202. **Vickers AJ**, Savage CJ. New prognostic markers: the pathway from research to clinical practice. Grand Rounds in Urology. 2009;8(3):7-13.
203. Deng G, Lin H, Seidman A, Fornier M, D'Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, **Vickers AJ**, Cassileth B. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of Cancer Research and Clinical Oncology. 2009;135(9):1215-21.
204. **Vickers AJ**, Maschino AC. The Acupuncture Trialists' Collaboration: individual patient data meta-analysis of chronic pain trials. Acupuncture in Medicine. 2009;27(3):126-7.
205. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Jr., Yossepowitch O, **Vickers AJ**, Klein EA, Wood DP, Scardino PT. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. Journal of Clinical Oncology. 2009;27(26):4300-5.
206. Shariat SF, Kattan MW, **Vickers AJ**, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncology. 2009;5(10):1555-84.
207. Challacombe BJ, Murphy D, Lilja H, **Vickers AJ**, Costello AJ. The continuing role of prostate-specific antigen asa merker for localized prostate cancer: 'do not throw the baby out with the bathwater'. British Journal of Urology International. 2009;104(11):1553-4
208. Cassileth BR, Rizvi N, Deng G, Yeung KS, **Vickers A**, Guillen S, Woo D, Coleton M, Kris MG. Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 2009;65(1):67-71.
209. Savage CJ, **Vickers AJ**. Low annual caseloads of United States surgeons conducting radical prostatectomy. Journal of Urology. 2009;182(6):2677-9.
210. **Vickers AJ**, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer. 2009;115(23):5460-9.
211. **Vickers AJ**, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Pettersson K, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schroder FH, Lilja H. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. European Urology. 2009;56(5):753-60.
212. Steyerberg EW, **Vickers AJ**, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128-38.
213. Hrynaszkiewicz I, Norton ML, **Vickers AJ,** Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. British Medical Journal. 2010;340:c181.
214. Hrynaszkiewicz I, Norton ML, **Vickers AJ**, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials. 2010; 29;11:9.
215. **Vickers AJ,** Cronin AM. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Seminars in Oncology. 2010;37(1):31-8.
216. **Vickers AJ,** Savage CJ, Lilja H. Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? Journal of Clinical Oncology. 2010;28(7):1112-6.
217. **Vickers AJ**. Reducing systematic review to a cut and paste. Forsch Komplementmed. 2010;17(6):303-5.

218. Cronin AM, Godoy G, **Vickers AJ**. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. Journal of Urology. 2010;183(3):984-9.
219. Bianco FJ Jr, **Vickers AJ**, Cronin AM, Klein EA, Eastham JA, Pontes JE, Scardino PT. Variations among experienced surgeons in cancer control after open radical prostatectomy. Journal of Urology. 2010;183(3):977-82.
220. **Vickers AJ**, Fearn P, Scardino PT, Kattan MW. Why can't nomograms be more like netflix? Urology. 2010;75(3):511-3.
221. **Vickers AJ**, Cronin AM, Masterson TA, Eastham JA. How do you tell whether a change in surgical technique leads to a change in outcome? Journal of Urology. 2010;183(4):1510-4.
222. Bianco FJ, Cronin AM, Klein EA, Pontes JE, Scardino PT, **Vickers AJ**. Fellowship training as a modifier of the surgical learning curve. Academic Medicine. 2010;85(5):863-8.
223. Savage CJ, Lilja H, Cronin AM, Ulmert D, **Vickers AJ**. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiology, Biomarkers, and Prevention. 2010;19(5):1201-7.
224. Klein RJ, Halldén C, Cronin AM, Ploner A, Wiklund F, Bjartell AS, Stattin P, Xu J, Scardino PT, Offit K, **Vickers AJ,** Grönberg H, Lilja H. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prevention Research (Phila Pa). 2010;3(5):611-9.
225. Gallagher DJ, Vijai J, Cronin AM, Bhatia J, **Vickers AJ**, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, Dutra-Clarke A, Klein RJ, Scardino PT, Eastham JA, Lilja H, Kirchhoff T, Offit K. Susceptibility loci associated with prostate cancer progression and mortality. Clinical Cancer Research. 2010;16(10):2819-32.
226. Pfister DG, Cassileth BR, Deng GE, Yeung KS, Lee JS, Garrity D, Cronin A, Lee N, Kraus D, Shaha AR, Shah J, **Vickers AJ**. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. Journal of Clinical Oncology. 2010;28(15):2565-70.
227. **Vickers AJ**, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer. 2010;116(11):2612-20.
228. **Vickers AJ**, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. Journal of Urology. 2010 184(3):907-12.
229. **Vickers AJ**, Salz T, Basch E, Cooperberg MR, Carroll PR, Tighe F, Eastham J, Rosen RC. Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Medical Informatics and Decision Making. 2010;10:34.
230. **Vickers AJ**, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schröder FH, Lilja H. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clinical Cancer Research. 2010;16(12):3232-9.

231. Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, **Vickers AJ**, Schröder FH, Lilja H. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. British Journal of Cancer. 2010;103(5):708-14. PubMed PMID: 20664589; PubMed Central PMCID: PMC2938258.
232. Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, **Vickers A**, Scardino PT. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. Journal of Clinical Oncology. 2010;28(9):1508-13.
233. **Vickers A**. Prediction models in urology: are they any good, and how would we know anyway? European Urology. 2010;57(4):571-3. PubMed PMID: 20071072; PubMed Central PMCID: PMC2891896.
234. **Vickers A**, Bianco F, Cronin A, Eastham J, Klein E, Kattan M, Scardino P. The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. Journal of Urology. 2010;183(4):1360-5. PubMed PMID: 20171687; PubMed Central PMCID: PMC2861336.
235. Lowrance WT, Yee DS, Savage C, Cronin AM, O'Brien MF, Donat SM, **Vickers A**, Russo P. Complications after radical and partial nephrectomy as a function of age. Journal of Urology. 2010;183(5):1725-30.
236. Shariat SF, Lotan Y, **Vickers A**, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, Malats N. Statistical consideration for clinical biomarker research in bladder cancer. Urologic Oncology. 2010;28(4):389-400. PubMed PMID: 20610277; PubMed Central PMCID: PMC3407571.
237. **Vickers AJ**, Savage CJ, Shouery M, Eastham JA, Scardino PT, Basch EM. Validation study of a web-based assessment of functional recovery after radical prostatectomy. Health and Quality of Life Outcomes. 2010;8:82.
238. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, Shariat SF, **Vickers AJ**. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. European Urology. 2010;58(5):687-700.
239. **Vickers AJ**, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schröder FH, Lilja H. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clinical Cancer Research. 2010;16(17):4374-81.
240. **Vickers AJ**, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. British Medical Journal. 2010;341:c4521.
241. Tsalatsanis A, Hozo I, **Vickers A**, Djulbegovic B. A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making. BMC Medical Informatics and Decision Making. 2010;10:51. PubMed PMID: 20846413; PubMed Central PMCID: PMC2954854.
242. **Vickers AJ**, Cronin AM. Data and programming code from the studies on the learning curve for radical prostatectomy. BMC Research Notes. 2010;3:234.
243. **Vickers AJ**, Cronin AM, Maschino AC, Lewith G, Macpherson H, Victor N, Sherman KJ, Witt C, Linde K; Acupuncture Trialists' Collaboration. Individual patient data meta-

analysis of acupuncture for chronic pain: protocol of the Acupuncture Trialists' Collaboration. Trials. 2010 28;11:90.

244. Cooperberg MR, **Vickers AJ**, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226-34.
245. Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H, **Vickers A**. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer. 2010;10:635. PubMed PMID: 21092177; PubMed Central PMCID: PMC2996396.
246. Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, **Vickers AJ**, Wender RC, Brawley OW. Sixty years of CA: a cancer journal for clinicians. CA A Cancer Journal for Clinicians. 2010;60(6):345-50.
247. **Vickers AJ**, Cronin AM. Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology. 2010;76(6):1298-301.
248. Secin FP, Savage C, Abbou C, de La Taille A, Salomon L, Rassweiler J, Hruza M, Rozet F, Cathelineau X, Janetschek G, Nassar F, Turk I, Vanni AJ, Gill IS, Koenig P, Kaouk JH, Martinez Pineiro L, Pansadoro V, Emiliozzi P, Bjartell A, Jiborn T, Eden C, Richards AJ, Van Velthoven R, Stolzenburg JU, Rabenalt R, Su LM, Pavlovich CP, Levinson AW, Touijer KA, **Vickers A**, Guillonneau B. The learning curve for laparoscopic radical prostatectomy: an international multicenter study. Journal of Urology. 2010;184(6):2291-6.
249. **Vickers A,** Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schröder F, Lilja H. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. Journal of Clinical Oncology 2010;28(15):2493-8. PubMed PMID: 20421547; PubMed Central PMCID: PMC2881727.
250. O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G, Cuzick J, Møller H, Oliver RT, Berney DM, Foster CS, Eastham JA, **Vickers AJ**, Lilja H; on behalf of the Trans-Atlantic Prostate Group. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer. 2011;128(10):2373-2381.
251. **Vickers AJ**, Savage CJ, Bianco FJ, Klein EA, Kattan MW, Secin FP, Guilloneau BD, Scardino PT. Surgery confounds biology: The predictive value of stage, grade and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience. Int J Cancer. 2011;128(7):1697-702.
252. **Vickers AJ.** Surgical volumes and patient outcomes in urological oncology. AUA Update Series.
253. Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Wallström P, **Vickers AJ**, Lilja H. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol. 2012;61(3):471-7. PubMed PMID: 22101116; PubMed Central PMCID: PMC3269546.
254. **Vickers AJ**, Cronin AM, Begg CB. One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol. 2011;11:13.

255. Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, **Vickers AJ**, Guillonneau B, Scardino PT, Eastham JA. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. Journal of Urology. 2011;185(2):477-82.
256. **Vickers AJ**, Gupta A, Savage C, Pettersson K, Dahlin A, Bjartell AS, Manjer J, Scardino PT, Ulmert D, Lilja H. A panel of kallikrein markers predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev. 2011;20(2):255-61.
257. **Vickers A**, Eastham J. What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public? Urol Oncol. 2011;29(2):118-23. PubMed PMID: 20884248; PubMed Central PMCID: PMC3035760.
258. **Vickers A**, Savage C, Bianco F, Mulhall J, Sandhu J, Guillonneau B, Cronin A, Scardino P. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol. 2011;59(3):317-22. PubMed PMID: 21095055; PubMed Central PMCID: PMC3060298.
259. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, **Vickers AJ**. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2011;117(6):1210-9.
260. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011;103(6):462-9.
261. **Vickers AJ**. Great meaningless questions in urology: which is better, open, laparoscopic, or robotic radical prostatectomy? Urology. 2011 May;77(5):1025-6.
262. Bach PB, Vickers AJ. Do the data support the comorbidity hypothesis for the prostate, lung, colorectal, and ovarian cancer screening trial results? J Clin Oncol. 2011;29(13):e387.
263. **Vickers AJ**. Making raw data more widely available. BMJ. 2011;342:d2323.
264. Christensson A, Bruun L, Björk T, Cronin AM, **Vickers AJ**, Savage CJ, Lilja H. Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. BJU Int. 2011;107(11):1769-74.
265. Shariat SF, Semjonow A, Lilja H, Savage C, **Vickers AJ**, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncologica. 2011;50 Suppl 1:61-75.
266. Deng G, Kurtz RC, **Vickers A**, Lau N, Yeung KS, Shia J, Cassileth B. A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. J Ethnopharmacol. 2011;136(1):83-7.
267. **Vickers AJ**. Prediction models in cancer care. CA: Cancer J Clin. 2011;29(22):2951-2. PubMed PMID: 21732332; PubMed Central PMCID: PMC3189416.
268. Shariat SF, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, **Vickers AJ**. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: A decision-curve analysis. Cancer. 2011;117(13):2892-7. PubMed Central PMCID: PMC3334293.

269. **Vickers AJ**. Re: comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst. 2011;103(14):1134.
270. **Vickers AJ**. Prediction models: revolutionary in principle, but do they do more good than harm? J Clin Oncol. 2011;29(22):2951-2.
271. Godoy G, Chong KT, Cronin A, Vickers A, Laudone V, Touijer K, Guillonneau B, Eastham JA, Scardino PT, Coleman JA. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol. 2011;60(2):195-201.
272. **Vickers A**. Words of wisdom: Re: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. Eur Urol. 2011;60(2):392.
273. Cassileth BR, Van Zee KJ, Chan Y, Coleton MI, Hudis CA, Cohen S, Lozada J, **Vickers AJ**. A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema. Acupunct Med. 2011;29(3):170-2. PubMed PMID: 21685498; PubMed Central PMCID: PMC3171073.
274. Silberstein JL, Vickers AJ, Power NE, Fine SW, Scardino PT, Eastham JA, Laudone VP. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer. 2011;117(21):4855-60.
275. **Vickers AJ**, Lilja H. Urological cancer: Time for another rethink on prostate cancer screening. Nat Rev Clin Oncol. 2011;9(1):7-8.
276. **Vickers AJ**. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011 Nov 2;103(21):1635-6.
277. Sandhu JS, Maschino AC, **Vickers AJ**. The surgical learning curve for artificial urinary sphincter procedures compared to typical surgeon experience. Eur Urol. 2011;60(6):1285-9.
278. **Vickers AJ**, Roobol MJ, Lilja H. Screening for Prostate Cancer: Early detection or overdetection? Annu Rev Med. 2012;63:161-70. PubMed PMID: 22053739; PubMed Central PMCID: PMC3415315.
279. **Vickers AJ,** Lilja H. We need a better marker for prostate cancer. How about renaming PSA?. Urology. 2012;79(2):254-5.
280. **Vickers AJ**, Sjoberg D, Basch E, Sculli F, Shouery M, Laudone V, Touijer K, Eastham J, Scardino PT. How Do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. Eur Urol. 2012;61(2):284-9. PubMed PMID: 22078336; PubMed Central PMCID: PMC3381332.
281. Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, **Vickers AJ**, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest. 2012;42(2):216-228.
282. **Vickers AJ**, Bennette C, Touijer K, Coleman J, Laudone V, Carver B, Eastham JA, Scardino PT. Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy. Trials. 2012;13:23. PubMed PMID: 22364367; PubMed Central PMCID: PMC3298715.
283. Bennette C, **Vickers A**. Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol. 2012; 29;12:21.
284. **Vickers AJ,** Lilja H. PSA is dead, long live PSA. Eur Urol. 2012;61(3):467-8.

285. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, **Vickers A**. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int. 2012;109 Suppl 2:1-7.
286. **Vickers AJ**, Lilja H. Predicting prostate cancer many years before diagnosis: how and why? World J Urol. 2012;30(2):131-5. PubMed PMID: 22101902; PubMed Central PMCID: PMC3373007.
287. Roobol MJ, Schroder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, **Vickers AJ,** Lilja H, Steyerberg EW. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol. 2012;30(2):149-55. PubMed PMID: 22203238; PubMed Central PMCID: PMC3321270.
288. Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Stephen Jones J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schroder FH, Lilja H, **Vickers AJ**. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J. Urol. 2012;30(2):181-7.
289. Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schröder FH, **Vickers AJ**. Risk-based prostate cancer screening. Eur Urol. 2012;61(4):652-61. Carlsson S, **Vickers A**, Lilja H, Hugosson J. Screening for prostate cancer. Ann Intern Med. 2012;156(7):539; author reply 540.
291. Breitbart W, Poppito S, Rosenfeld B, **Vickers AJ**, Li Y, Abbey J, Olden M, Pessin H, Lichtenthal W, Sjoberg D, Cassileth BR. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. J Clin Oncol. 2012;30(12):1304-9.
292. Lughezzani G, Zorn KC, Budaus L, Sun M, Lee DI, Shalhav AL, Zagaya GP, Shikanov SA, Gofrit ON, Thong AE, Albala DM, Sun L, Cronin A, **Vickers AJ**, Karakiewicz PI. Comparison of Three Different Tools for Prediction of Seminal Vesicle Invasion at Radical Prostatectomy. Eur Urol. 2012 Oct;62(4):590-6.
293. Ulmert D, **Vickers AJ**, Scher HI, Becker C, Iversen P, Frankel D, Jensen JK, Kold Olesen T, Lilja H. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clin Chem Lab Med. 2012;30;0(0):1-6. PubMed PMID: 22718641; PubMed Central PMCID: PMC3474140.
294. Blajchman MA, Carson JL, Eikelboom JW, Heddle NM, Lacroix J, Lauer MS, Platt R, Tilley B, Triulzi D, **Vickers AJ**, Yusuf S, Glynn S, Mondoro TH, Wagner E. The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion. 2012;52(6):1363-78.
295. Silberstein JL, **Vickers AJ**, Power NE, Parra RO, Coleman JA, Pinochet R, Touijer KA, Scardino PT, Eastham JA, Laudone VP. Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures. J Endourol. 2012 Jun;26(6):748-53. PubMed PMID: 22050490; PubMed Central PMCID: PMC3357075

296. **Vickers AJ**, Bennette C, Kibel AS, Black A, Izmirlian G, Stephenson AJ, Bochner B. Who should be included in a clinical trial of screening for bladder cancer?: A decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer. 2013 Jan 1;119(1):143-9.
297. **Vickers AJ**, Brewster SF. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol. 2012;5(4):162-168.
298. **Vickers AJ**. The trifecta: great concept, lousy statistic. BJU Int. 2012 Sep;110(6):771-2.
299. Basch E, Oliver TK, **Vickers A**, Thompson I, Kantoff P, Parnes H, Loblaw DA, Roth B, Williams J, Nam RK. Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012 Aug 20;30(24):3020-5.
300. Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, **Vickers AJ**, Shariat SF. Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. Ann Surg Oncol. 2012 Dec;19(13):4337-44.
301. Carlsson S, **Vickers AJ**, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J. Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review. J Clin Oncol. 2012;30(21):2581-4.
302. **Vickers A**, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian prostate cancer group randomized trial. Eur Urol. 2012;62(2):204-9. PubMed PMID: 22541389; PubMed Central PMCID: PMC3389180.
303. Nam RK, Oliver TK, **Vickers AJ**, Thompson I, Kantoff PW, Parnes HL, Loblaw A, Roth BJ, Williams J, Temin S, Basch E. Prostate-specific antigen test for prostate cancer screening: american society of clinical oncology provisional clinical opinion. J Oncol Pract. 2012 Sep;8(5):315-7. PubMed PMID: 23277770;PubMed Central PMCID: PMC3439233.
304. **Vickers AJ**, Cronin AM, Gönen M. A simple decision analytic solution to the comparison of two binary diagnostic tests. Stat Med. 2012 Sep 13. PubMed PMID:22975863;PubMed Central PMCID: PMC3531575.
305. Forsberg JA, Sjoberg D, Chen QR, **Vickers A**, Healey JH. Treating Metastatic Disease: Which Survival Model Is Best Suited for the Clinic? Clin Orthop Relat Res. Clin Orthop Relat Res. 2013 Mar;471(3):843-50.
306. **Vickers AJ**, Eastham JA, Scardino PT. Radical prostatectomy versus observation for prostate cancer. N Engl J Med. 2012 Oct 11;367(15):1467-8; author reply 1468-9.
307. **Vickers AJ**, Cronin AM, Maschino AC, Lewith G, MacPherson H, Foster NE, Sherman KJ, Witt CM, Linde K; Acupuncture Trialists' Collaboration. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med. 2012 Oct 22;172(19):1444-53.
308. Deng G, Wong WD, Guillem J, Chan Y, Affuso T, Yeung KS, Coleton M, Sjoberg D, **Vickers A**, Cassileth B. A Phase II, Randomized, Controlled Trial of Acupuncture for Reduction of Postcolectomy Ileus. Ann Surg Oncol. Ann Surg Oncol. 2013 Apr;20(4):1164-9.

309. Haiman CA, Stram DO, **Vickers AJ**, Wilkens LR, Braun K, Valtonen-André C, Peltola M, Pettersson K, Waters KM, Marchand LL, Kolonel LN, Henderson BE, Lilja H. Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. J Natl Cancer Inst. 2013 Feb 6;105(3):237-43.
310. Van Calster B, **Vickers AJ**, Pencina MJ, Baker SG, Timmerman D, Steyerberg EW. Evaluation of Markers and Risk Prediction Models: Overview of Relationships between NRI and Decision-Analytic Measures. Med Decis Making. 2013 May;33(4):490-501.
311. Deng G, Chan Y, Sjoberg D, **Vickers A**, Yeung KS, Kris M, Straus D, Cassileth B. Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Support Care Cancer. 2013 Jun;21(6):1735-41
312. Silberstein JL, Su D, Glickman L, Kent M, Keren-Paz G, **Vickers AJ**, Coleman JA, Eastham JA, Scardino PT, Laudone VP. A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int. 2013 Feb;111(2):206-12
313. Carlsson S, **Vickers A**, Hugosson J. Four-hundredfold overestimation of biopsy mortality. BJU Int. 2013 Mar;111(3):E16-7.
314. Carlsson SV, Peltola MT, Sjoberg D, Schröder FH, Hugosson J, Pettersson K, Scardino PT, **Vickers AJ**, Lilja H, Roobol MJ. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int. 2013 Feb 28.
315. **Vickers AJ**, Maschino AC, Lewith G, MacPherson H, Sherman KJ, Witt CM; Acupuncture Trialists' Collaboration. Responses to the Acupuncture Trialists' Collaboration individual patient data meta-analysis. Acupunct Med. 2013 Mar;31(1):98-100.
316. van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, **Vickers A**, van der Poel HG. Timing of curative treatment for prostate cancer: a systematic review. Eur Urol. 2013 Aug;64(2):204-15.
317. Christensson A, Savage C, Sjoberg DD, Cronin AM, Frank O'Brien M, Lowrance W, Nilsson PM, **Vickers AJ**, Russo P, Lilja H. Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer. 2013 Sep 15;133(6):1452-8.
318. **Vickers AJ**. Prostate cancer: Why is PSA velocity such a sticky concept? Nat Rev Urol. 2013 Apr;10(4):189-90.
319. **Vickers AJ**. Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer. J Natl Compr Canc Netw. 2013 Mar 1;11(3):286-90.
320. **Vickers AJ**, Pencina M. Prostate-specific Antigen Velocity: New Methods, Same Results, Still No Evidence of Clinical Utility. Eur Urol. 2013 Sep;64(3):394-6.
321. **Vickers AJ**. Writing Up Clinical Research: A Statistician's View. J Gen Intern Med. 2013 Sep;28(9):1127-9.
322. Cassileth BR, Van Zee KJ, Yeung KS, Coleton MI, Cohen S, Chan YH, **Vickers AJ**, Sjoberg DD, Hudis CA. Acupuncture in the treatment of upper-limb lymphedema: Results of a pilot study. Cancer. 2013 Jul 1;119(13):2455-61.
323. **Vickers AJ**, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013 Apr 15;346:f2023.

324. Trinh QD, Bjartell A, Freedland SJ, Hollenbeck BK, Hu JC, Shariat SF, Sun M, **Vickers AJ**. A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. Eur Urol. 2013 Nov;64(5):786-98.
325. Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, van Leenders G, **Vickers A**, Lilja H, Roobol MJ. Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam. Eur Urol. 2013 Nov;64(5):693-9.
326. Arsov C, Becker N, Hadaschik BA, Hohenfellner M, Herkommer K, Gschwend JE, Imkamp F, Kuczyk MA, Antoch G, Kristiansen G, Siener R, Semjonow A, Hamdy FC, Lilja H, **Vickers AJ**, Schröder FH, Albers P. Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial. Eur Urol. 2013 Dec;64(6):873-5.
327. **Vickers AJ**, Sjoberg DD, Ankerst DP, Tangen CM, Goodman PJ, Thompson Jr IM. The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer. 2013 Aug 15;119(16):3007-11.
328. **Vickers AJ**, Altman DG. Statistics notes: missing outcomes in randomised trials. BMJ. 2013 Jun 6;346:f3438.
329. Modak S, Kushner BH, Kramer K, **Vickers A**, Cheung IY, Cheung NK. Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology. 2013 Mar 1;2(3):e23402.
330. **Vickers AJ**. If something looks too good to be true, it probably is. BJU Int. 2013 Aug;112(4):430-1.
331. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, **Vickers AJ**, Shariat SF. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013 Sep 17;109(6):1460-6. PMCID: PMC3776972
332. Holmberg L, **Vickers A**. Evaluation of prediction models for decision-making: beyond calibration and discrimination. PLoS Med. 2013;10(7).
333. **Vickers A**. Words of wisdom: Re: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Eur Urol. 2013 Oct;64(4):682-3.
334. Braun K, Ahallal Y, Sjoberg DD, Ghoneim T, Dominguez Esteban M, Mulhall J, **Vickers A**, Eastham J, Scardino PT, Touijer KA. Effect of repeated prostate biopsies on erectile function in men on active surveillance for prostate cancer. J Urol. 2014 Mar;191(3):744-9.
335. MacPherson H, Maschino AC, Lewith G, Foster NE, Witt C, **Vickers AJ**; Acupuncture Trialists' Collaboration. Characteristics of acupuncture treatment associated with outcome: an individual patient meta-analysis of 17,922 patients with chronic pain in randomised controlled trials. PLoS One. 2013 Oct 11;8(10):e77438.
336. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, Lotan Y, Bachmann A, Zerbib M, Fisch M, Scherr DS, **Vickers A**, Shariat SF. Gender-specific Differences in Clinicopathologic Outcomes Following Radical

Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. Eur Urol. 2014 Nov;66(5):913-9.

337. Chan AW, Song F, **Vickers A**, Jefferson T, Dickersin K, Gøtzsche PC, Krumholz HM, Ghersi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014 Jan 18;383(9913):257-66.
338. **Vickers A**, Carlsson S, Laudone V, Lilja H. It Ain't What You Do, It's the Way You Do It: Five Golden Rules for Transforming Prostate-Specific Antigen Screening. Eur Urol. 2014 Aug;66(2):188-90.
339. Väänänen RM, Lilja H, Kauko L, Helo P, Kekki H, Cronin AM, **Vickers AJ**, Nurmi M, Alanen K, Bjartell A, Pettersson K. Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens. Urology. 2014 Feb;83(2):511.e1-7.
340. Bancroft EK, Page EC, Castro E, Lilja H, **Vickers A**, Sjoberg D, Assel M, Foster CS, et al. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. Eur Urol. 2014 Sep;66(3):489-99.
341. **Vickers AJ**, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med. 2014 Feb 11;12:26.
342. Silberstein JL, Poon SA, Sjoberg DD, Maschino AC, **Vickers AJ**, Bernie A, Konety BR, Kelly WK, Eastham JA. Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer. BJU Int. 2014 Feb 19. [Epub ahead of print]
343. **Vickers AJ**, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology. 2014 Mar;83(3):592-6.
344. Stattin P, Carlsson S, Holmström B, **Vickers A**, Hugosson J, Lilja H, Jonsson H. Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst. 2014 Mar;106(3):dju007.
345. **Vickers AJ**. What are the implications of the surgical learning curve? Eur Urol. 2014 Mar;65(3):532-3.
346. **Vickers AJ**, Linde K. Acupuncture for chronic pain. JAMA. 2014 Mar 5;311(9):955-6.
347. Carlsson S, Berglund A, Sjoberg D, Khatami A, Stranne J, Bergdahl S, Lodding P, Aus G, **Vickers A**, Hugosson J. Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urol. 2014 Mar 6;14:25.
348. Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, **Vickers A**. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ. 2014 Mar 28;348:g2296.
349. Weiss CO, Varadhan R, Puhan MA, **Vickers A**, Bandeen-Roche K, Boyd CM, Kent DM. Multimorbidity and evidence generation. J Gen Intern Med. 2014 Apr;29(4):653-60.
350. Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, **Vickers A**, Wilt T, Emberton M; the Prostate Cancer RCT Consensus Group. Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol. 2014 Apr 22.

351. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, **Vickers A**, Shariat SF. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urol Oncol. 2014 May;32(4):433-40.
352. Carroll PR, **Vickers AJ**. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences? J Natl Compr Canc Netw. 2014 May;12(5 Suppl):768-71.
353. Ankerst DP, Hoefler J, Bock S, Goodman PJ, **Vickers A**, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014 Jun;83(6):1362-7.
354. Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Dalpiaz O, Zigeuner R, Aziz A, Fritsche HM, Deliere A, Raman JD, Bensalah K, Al-Matar B, Gakis G, Novara G, Klatte T, Remzi M, Comploj E, Pycha A, Rouprêt M, Tagawa ST, Chun FK, Scherr DS, **Vickers AJ**, Shariat SF. Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU Int. 2014 Jun;113(6):911-7.
355. **Vickers AJ**, Kent M, Mulhall J, Sandhu J. Counseling the Post-radical Prostatectomy Patients About Functional Recovery: High Predictiveness of Current Status. Urology. 2014 Jul;84(1):158-63.
356. Matignon M, Ding R, Dadhania DM, Mueller FB, Hartono C, Snopkowski C, Li C, Lee JR, Sjoberg D, Seshan SV, Sharma VK, Yang H, Nour B, **Vickers AJ**, Suthanthiran M, Muthukumar T. Urinary Cell mRNA Profiles and Differential Diagnosis of Acute Kidney Graft Dysfunction. J Am Soc Nephrol. 2014 Jul;25(7):1586-1597.
357. Vertosick EA, Poon BY, **Vickers AJ**. Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol. 2014 Sep;192(3):724-8.
358. MacPherson H, Vertosick E, Lewith G, Linde K, Sherman KJ, Witt CM, **Vickers AJ**; Acupuncture Trialists' Collaboration. Influence of control group on effect size in trials of acupuncture for chronic pain: a secondary analysis of an individual patient data meta-analysis. PLoS One. 2014 Apr 4;9(4):e93739. PMCID: PMC3976298
359. **Vickers AJ**, Sjoberg DD. Guidelines for Reporting of Statistics in European Urology. Eur Urol. 2015 Feb;67(2):181-7.
360. Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, **Vickers AJ**, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P. Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. Mol Cell Proteomics. Mol Cell Proteomics. 2014 Nov;13(11):3082-96.
361. Van Calster B, **Vickers AJ**. Calibration of Risk Prediction Models: Impact on Decision-Analytic Performance. Med Decis Making. 2015 Feb;35(2):162-9.
362. Fossati N, Sjoberg DD, Capitanio U, Gandaglia G, Larcher A, Nini A, Mirone V, **Vickers AJ,** Montorsi F, Briganti A. Extended Pelvic Lymph Node Dissection in Prostate Cancer Patients Previously Treated With Surgery for Lower Urinary Tract Symptoms. BJU Int. 2014 Aug 28. [Epub ahead of print]
363. Vedder MM, de Bekker-Grob EW, Lilja HG, **Vickers AJ**, van Leenders GJ, Steyerberg EW, Roobol MJ. The Added Value of Percentage of Free to Total Prostate-specific

Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men. Eur Urol. 2014 Aug 25. Eur Urol. 2014 Dec;66(6):1109-15.

364. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, **Vickers AJ**, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219.
365. **Vickers AJ**, Edwards K, Cooperberg MR, Mushlin AI. A simple schema for informed decision making about prostate cancer screening. Ann Intern Med. 2014 Sep 16;161(6):441-2.
366. **Vickers AJ**. Clinical trials in crisis: Four simple methodologic fixes. Clin Trials. 2014 Oct 1. Clin Trials. 2014 Dec;11(6):615-21.
367. Brockman JA, Alanee S, **Vickers AJ**, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco Jr FJ, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. Eur Urol. 2015 Jun;67(6):1160-7.
368. **Vickers AJ.** Markers for the early detection of prostate cancer: some principles for statistical reporting and interpretation. J Clin Oncol. 2014 Dec 20;32(36):4033-4.
369. Kent M, **Vickers AJ**. A systematic literature review of life expectancy prediction tools for localized prostate cancer patients. J Urol. 2015 Jun;193(6):1938-42.
370. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, **Vickers AJ**, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Ann Intern Med. 2015 Jan 6;162(1):W1-W73.
371. **Vickers AJ**, Sjoberg DD. Decision analysis of dutasteride use for patients with negative prostate biopsy. Urology. 2015 Feb;85(2):337-41.
372. Strobl AN, Thompson IM, **Vickers AJ**, Ankerst DP. The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape. J Urol. 2015 Jul;194(1):58-64.
373. Stattin P, **Vickers AJ**, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Lilja H. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol. 2015 Feb 11. [Epub ahead of print]
374. Matsushita K, Kent MT, **Vickers AJ**, von Bodman C, Bernstein M, Touijer KA, Coleman JA, Laudone VT, Scardino PT, Eastham JA, Akin O, Sandhu JS. Preoperative predictive model of recovery of urinary continence after radical prostatectomy. BJU Int. 2015 Feb 13. [Epub ahead of print]
375. Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, **Vickers AJ**, Xylinas E, Shariat SF. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015 Feb 20. [Epub ahead of print]
376. **Vickers AJ**. Four flawed arguments against prostate-specific antigen screening (and 1 good one). Urology. 2015 Mar;85(3):491-4.
377. Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, Goodman KA, Johansen C, Matasar MJ, de Nully Brown P, Oeffinger KC, **Vickers AJ**.

Are we ready to predict late effects? A systematic review of clinically useful prediction models. Eur J Cancer. 2015 Apr;51(6):758-66.

378. **Vickers AJ**. Informed decision making about prostate cancer screening. Ann Intern Med. 2015 Mar 17;162(6):457-8.
379. Nieboer D, Vergouwe Y, Roobol MJ, Ankerst DP, Kattan MW, **Vickers AJ**, Steyerberg EW; Prostate Biopsy Collaborative Group. Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group. J Clin Epidemiol. 2015 Apr;68(4):426-34.
380. Fossati N, Passoni NM, Moschini M, Gandaglia G, Larcher A, Freschi M, Guazzoni G, Sjoberg DD, **Vickers AJ**, Montorsi F, Briganti A. Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU Int. 2015 Mar 17. [Epub ahead of print]
381. Bryant RJ, Sjoberg DD, **Vickers AJ**, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC. Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. J Natl Cancer Inst. 2015 Apr 11;107(7).
382. **Vickers AJ**, Kent DM. The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk. Ann Intern Med. 2015 Jun 16;162(12):866-7.
383. Imnadze M, Sjoberg DD, **Vickers AJ**. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes. Eur Urol. 2015 Apr 23. [Epub ahead of print]
384. Braun K, Sjoberg DD, **Vickers AJ**, Lilja H, Bjartell AS. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol. 2015 May 12. [Epub ahead of print]
385. Strobl AN, **Vickers AJ**, van Calster B, Steyerberg E, Leach RJ, Thompson IM, Ankerst DP. Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific cancer risk calculators. J Biomed Inform. 2015 May 16. [Epub ahead of print]
386. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, **Vickers AJ**, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2015 Jul 9. [Epub ahead of print]

Books, book chapters and reviews.

1. **Vickers AJ.** Complementary Medicine and Disability. London: Chapman and Hall (1993).
2. **Vickers AJ**. Health Options: complementary therapies for cerebral palsy and related conditions. Shaftesbury: Element Books in association with the Spastics Society (1994).
3. **Vickers AJ**. Massage and Aromatherapy: a guide for health professionals. London: Chapman and Hall (1996). Reprinted by: Cheltenham: Stanley Thornes (1998).
4. **Vickers AJ**. Research paradigms in mainstream and complementary medicine. In: Ernst E (Ed.). Complementary Medicine: an objective appraisal. Oxford: Butterworth Heinemann (1996).
5. **Vickers AJ** (Ed.). Examining Complementary Medicine: the Sceptical Holist. Cheltenham: Stanley Thornes (1998).

6. **Vickers AJ**. Criticism, scepticism and complementary medicine. In: **Vickers AJ** (Ed.). Examining Complementary Medicine: the Sceptical Holist. Cheltenham: Stanley Thornes (1998).
7. **Vickers AJ**. Promoting rigorous research: the work of the Research Council for Complementary Medicine. In: Meade T (Ed.). Science-based complementary medicine. London: Royal College of Physicians (1998).
8. **Vickers AJ**. Complementary therapies in sports medicine. In: Carder G. Sports & Exercise Medicine For Doctors by Distance Learning, Rehabilitation Module. Bath: University of Bath (1998).
9. Zollman CE, **Vickers AJ**. ABC of complementary medicine. London: British Medical Journal Publishing (2000).
10. **Vickers AJ**. Complementary medicine. In: Sackett D, Straus S, Richardson S, Rosenberg W & Haynes B (Eds). Evidence-Based Medicine: How to Practise and Teach EBM. London: Harcourt Brace (2000).
11. **Vickers AJ**, Cassileth BR. Complementary and alternative medicine approaches in colorectal cancer. In: Colorectal cancer: multimodality management. Ed by Saltz L. Totowa, NJ: Humana (2002).
12. Cassileth BR, **Vickers AJ**. Questionable cancer therapies. In: Cancer Medicine Ed by JF Holland, E Frei, R Bast, D Kufe, R Pollock, R Weichselbaum. Hamilton, Canada: BC Decker Inc, 2002.
13. **Vickers AJ**, Zollman CE. Complementary therapies. In: Jones R, Britten N, Culpepper L, Gass D, Grol R, Mant D, Silagy C, editors. Oxford Textbook of Primary Medical Care. Oxford: Oxford University Press, 2003.
14. Cassileth BR, **Vickers AJ**. Complementary therapy. In: Prostate Cancer. Ed by P Carroll and A D'Amico. New York: Lippincott, Williams and Wilkins 2004.
15. Cassileth BR, Deng G, **Vickers AJ**, Yeung KS. PDQ: integrative oncology. Hamilton, Canada: BC Decker (2005).
16. Deng G, **Vickers AJ**, Yeung KS, Cassileth BR. Acupuncture in Cancer Patient Care. In: Current Review of Chinese Medicine. Ed by Ping-chung Leung, Harry Fong and Charlie Changli Xue. Singapore: World Scientific Publishing Co. 2006.
17. **Vickers AJ**. Analyzing change from baseline in randomized trials. In: D'Agostino R, Sullivan L and Massaro J, editors. Wiley Encyclopedia of Clinical Trials. Wiley Interscience: 2007.
18. **Vickers AJ.** Decision curve analysis. In: Kattan MW, ed. Encyclopedia of Medical Decision Making. New York, NY: Sage Publications, 2009.
19. **Vickers AJ**. What is a p value anyway? 34 stories to help you actually understand statistics. Boston, MA: Addison-Wesley, 2009.
20. **Vickers AJ**, Maschino A, Savage C, Cronin AM, and Patel VP. Assessing the Learning Curve for Prostate Cancer Surgery In: Robotic Urologic Surgery. Editor Patel, VP. Springer London, 2012.

Date: 7/15/15

Signature: A. Vi